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ABSTRACT 
A previous study in the Drover laboratory found that IL-6 and HLA-DR52 were 
associated with increased breast tumor size and decreased recurrence free survival (RFS). 
Since IL-6, along with TGF-p, is required for the differentiation of na·ive T cells into T H 17 
cells, we hypothesized that the number ofT H 17 cells would be increased in HLA-DR52+ 
tumors and statistically associate with both larger tumors and decreased RFS. 
Following polymerase chain reaction (PCR) analysis of retinoic acid receptor-
related orphan receptor C2 (RORc2) and IL-17 transcripts, we developed a T H 17 cell 
profile. Statistical analysis did not reveal associations between T H 1711i, IL-6hi or HLA-
DR52+ tumors. Both IL-17hi and T H 17hi correlated with younger age of diagnosis. Further 
analysis revealed that T H 1711i/HLA-DR52+ tumors had the youngest age of diagnosis. There 
were no significant associations with decreased RFS or overall survival (OS). Yet, both IL-
1711i and T H 1711i trended with decreased OS. Future studies should expand on the sample 
size and determine if these associations and trends remain in a larger sample. 
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Chapter 1: Introduction 
1.1. Preface 
Previous work in the Drover laboratory focused on CD4+ T cells, and the 
correlation of tumoral lymphocytes with human leukocyte antigen (HLA)-DR 
phenotypes, prognosis and survival. In total , 85 breast tumors were examined by both 
immunohistochemistry (IHC) for immune infiltrates and reverse transcriptase polymerase 
chain reaction (RT -PCR) for the presence of various cytokine messenger ribonucleic acid 
(mRNA) transcripts. IHC provided characterization of the numbers and pattern of 
inflammatory cell infiltration and RT-PCR allowed relative levels of intratumoral 
cytokine or transcription factor mRNA to be quantified. A type 1 helper T (T H 1) cell 
profile was identified by high levels (greater than the 75 percenti le) of T HI type 
cytokines: interferon (IFN)-y, interleukin (IL)-2 and IL-1 2. A type 2 helper T (T H2) cell 
profile was identified by high levels of IL-4 and IL-l 0 transcripts. Forkhead box P3 
(FOXP3) positive regulatory T (Treg) cell profile was defined by high levels of FOXP3 
transcripts. Inflammatory T cell profiles were identified by IL-6 and IL- l ~ transcripts. 
Dual staining IHC was also used to detennine the presence of FOXP3 (nucleus) and CD4 
or CD25 (cytoplasm) in paraffin embedded breast tumors samples in a later study. 
Although most of the mRNA transcripts were analyzed by RT-PCR, and ideally should be 
confinned by real time PCR, the data revealed several important trends. High levels of 
IFN-y transcripts, detected by both RT-PCR and qPCR, correlated with increased survival 
of patients, whereas high IL-6 levels and HLA-DR52 were associated with large tumors 
and decreased survival (Oldford et al, 2006). As IL-6 is required for the commitment and 
differentiation of a na"ive T cell into aT H 17 cell (Bettelli et al. , 2008), we first questioned 
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ifT 1-117 cells were present in tumors with high IL-6. Secondly, ifT 1-117 cells were present, 
we predicted these cells would be increased in HLA-DR52+ patients and associate wi th 
decreased survival. We also intended to expand on this work by analyzing markers 
associated with T 1-117 cells and their association with prognostic indicators. Thus, the 
following chapter is divided into sections that provide a brief overview of breast 
carcinoma and a more detailed description ofT 1-117 cells and immune responses in cancer. 
1.2. Breast Carcinoma 
Breast carcinoma nonnally originates in breast tissue of the ducts or the lobules 
(Figure 1.1). Ductal carcinoma begins in ducts that facilitate the movement of milk from 
the breast to nipple. Generally, ductal cancer is more common than lobular breast cancer, 
which originates in the area of the breast that produces milk, the lobules. Further, both 
ductal and lobular breast cancer can be defined as either non-invasive/in situ, meaning the 
cancer is confined to the layer of cells where it began or invasive, meaning the cancer has 
grown beyond the originating cell layer. Ductal carcinoma in situ (DCIS) is the most 
common non-invasive breast cancer. Nearly 1/5 of new breast cancer cases are DCIS and 
the prognosis for these patients is favorable because early DCIS diagnoses are associated 
with high survival (Ernster, eta!. , 2002). 
2 
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Figure 1.1. Normal structure of a breast. The most common tissues where breast cancer 
develops are the ducts and the lobules. The ducts supply milk to the nipple and the 
lobules produce the milk. Typically, breast carcinoma will arise in either the lobules or 
the ducts. Both the lobules and the ducts are illustrated above. 
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Lobular carcinoma in situ (LCIS) is less common than DCIS. Invasive ductal 
carcinoma (IDC) is the most common type of breast cancer. IDC begins in the milk duct 
and cancerous cells break through the wall of the duct and these cells proliferate in the 
fatty tissue of the breast. The cancer cells can then metastasize to other areas of the body 
through the lymphatic system and blood stream. Roughly eighty percent of invasive 
cancers are IDC (Carlson et al. , 2009, McPherson et al., 2000). Invasive lobular cancer 
(ILC) begins in the lobules and can spread to other parts of the body (Carlson et al. , 2009, 
McPherson et al. , 2000). 
Breast cancers originating in tissues other than ducts and lobules are uncommon. 
Of these, inflammatory breast cancer (IBC) accounts for I - 6% of these diagnoses 
(Wingo et al. , 2004). IBC occurs when cancer cells block lymph vessels in the skin and is 
not characterized by a lump and therefore, is difficult to detect (Wingo et al. , 2004). 
Medullary, mucinous, tubular and metaplastic carcinomas are examples of rare types of 
invasive breast cancers. Paget's disease of the nipple is a type of breast cancer that 
initiates in the ducts and spreads to the nipple and the areola. Paget's disease of the 
nipple is extremely rare, accounting for only 1% of diagnoses and is often associated wi th 
DCIS. With each different kind of breast carcinoma, unique treatment plans must be 
developed (Allred, D.C., 2008). 
1.2.1. Epidemiology of Breast Cancer 
In 201 2, an estimated 22,700 Canadian women and 200 Canadian men wi II be 
diagnosed with breast cancer. Despite the high number of new cases, the survival rates 
4 
are encouraging. It is estimated that 87% of the women and 84% of the men diagnosed 
will survive at least 5 years post diagnoses (Canadian Cancer Statistics, 20 12). 
The incidence of developing breast cancer is influenced by many factors. Men 
with breast cancer comprise less than 1% of new breast cancer cases. Women, in 
comparison, are almost 100 times more likely to develop the disease than men. Further, 
as individuals age, the risk of developing breast cancer rises. Among the 22,700 women 
diagnosed in 2012, approximately 80% of the cases occurred in women over 50 
(Canadian Cancer Statistics, 2012). 
Women who had an early menarche (before 12 years) or a late menopause (after 
55 years) were more likely to have increased incidences of breast cancer than those who 
had neither an early menarche or late menopause (Carlson et al. , 2009, McPherson et al,. 
2000). Following menarche, the ovaries secrete estrogen, estradiol and progesterone in a 
cyclic pattern based upon the menstrual cycle. The secretions of these hormones tend to 
fluctuate as a woman approaches menopause and the ovaries ultimately cease production 
of estradiol, estrogen and progesterone at the end of menopause (Burger, 1994). Earlier 
menarche and later menopause means a prolonged production of estrogen in the body and 
there is reliable evidence to suggest that elevated estrogen levels increase the risk of 
developing breast cancer (Yager and Davidson, 2006) 
Studies have found links and potential mechanisms between estrogen and 
development of cancer in various tissues including the kidneys, liver, uterus and breast. 
After estrogen (or estradiol) binds to an estrogen receptor (ER), the estrogen IS 
internalized and the cell will commence a series of reactions to eliminate the estrogen. In 
the case of expression of metabolizing carcinogenic estrogens, the reactions can produce 
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oxygen radicals. Oxygen radicals can be damaging to DNA. The damaged 
deoxyribonucleic acid (DNA) can result in mutations, leading to the promotion of cancer 
(Yager and Davidson, 2006). Furthennore, breast cancer is frequently hormone 
dependent and cancer cells express receptors for honnones. Therefore, honnones, such as 
estrogen and progesterone can stimulate cancer cells to grow. Conversely, proliferative 
cancer cells can be down-regulated by anti-hormones. As a result, tamoxifen, an 
antagonist of the ER, is the preferred treatment for ER+ breast cancer (Bai and Gust, 
2009). 
Family history and genetics are also indicators for the likelihood of developing 
breast cancer. Generally, a fami ly history of breast, uterine, ovarian or colon cancer 
increases an individual's risk of developing breast cancer (Wooster eta!, 1994; Rastelli et 
a!, 2011 ). Furthermore, genetic defects, particularly in breast cancer 1 (BRCAl) and 
breast cancer 2 (BRCA2) genes, increase an individual's chance of developing breast 
cancer. BRCAl and BRCA2 are tumor suppressor proteins; the former is involved in 
DNA repair and the latter in chromosomal repair (Wooster et a!, 1994; Rastelli et a!, 
2011 ). Women with defects in these genes, leading to improper production of the 
protective proteins, have an 80% chance of developing breast cancer (Carlson, 2009; 
Gage, 2012). However, these genetic defects account for a minority of breast cancer 
cases (between 5- 10%) (Gage, 20 12). 
In addition to the aforementioned factors , external and environmental factors play 
a role in breast cancer development. Such external risk factors can be the frequency of 
consumption of alcohol, smoking, age of first childbirth (honnonal link) and incidence of 
radiation exposure or honnone replacement therapies (Carlson et al. , 2009). 
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1.2.2. Classification and Treatment of Breast Carcinoma 
Breast cancer is classified and staged on the basis of several clinicopathologic 
factors. The stage is detennined using the tumor, node, metastases (TNM) classification 
of malignant tumors (frvin and Carey, 2008). The letter Tis followed by a number, either 
0 to 4 and describes the size of the tumor. A category of TO means that there is no 
evidence of a primary tumor, Tl indicates that the tumor is less than 2 em in diameter, T2 
indicates the tumor is between 2 and 5 em in diameter, T3 indicates a tumor greater than 5 
em in diameter, and T4 is representative of a tumor of any size growing into the chest 
wall or skin and is typical of inflammatory breast cancer. The letter N, for node, is be 
followed by a number between 0 and 3 and indicates whether the cancer has spread to 
nearby lymph nodes. As the numbers increase, the number and severity of lymph nodes 
invaded by cancer cel ls increases. Lastly, the letter M is followed by either a 0 or I and 
indicates whether or not the cancer has metastasized to distant organs. Taking the TNM 
categories into consideration the breast cancer is then staged between stage I (least 
advanced breast cancer) and stage IV (most advanced breast cancer). Appendix A 
provides characterization of breast cancer stages according to TNM (Irvin and Carey, 
2008; Michaud et al. , 2008). 
Tumor grade is also used to classify breast tumors. Most classification schemes 
for tumor differentiation are based on the scheme proposed by Bloom and Richardson 
(Bloom and Richardson, 1957). Tumors are assigned qualitative scores between l - 3 for 
tubule fonnation, nuclear pleiomorphism and mitotic rate. The three scores are then 
combined to assign a tumor a grade from 3 - 9. Tumors are then further divided into low 
(Grade I, scores 3-5), intennediate (Grade II, scores 6-7) and high (Grade III, scores 8-9). 
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Patients with Grade [ tumors show improved 5, 10, and 15 year survival in comparison to 
patients who have Grade [1/[J[ tumors (Bloom and Richardson, 1957). A common 
modification of this system, Nottingham System, uses a semi-quantitative assessment of 
the three factors mentioned by Bloom and Richardson for a more objective system for 
histological grade. Tumors are classified as well-differentiated (Grade I, scores 3-5), 
moderately differentiated (Grade II, scores 6-7), and poorly differentiated (Grade III, 
scores 8-9). Similar to the Bloom and Richardson system (1957), patients with lower 
tumor grades have improved disease free survival (Elston and Ellis, 1991 ). 
[n addition to the TNM system, there are other clinicopathologic factors, which 
can serve as prognostic indicators and aid in the determination of an appropriate 
treatment. Breast cancer cells may express ER and progesterone receptors (PR) 
(frequently analyzed together), and the human epidennal growth factor receptor 2 (HER2) 
(Irvin and Carey, 2008). Estrogen or progesterone binding to their respected receptor can 
lead to the proliferation and growth of breast cancer cells. Therefore, an appropriate 
treatment of ER+/PR+ breast cancer would be to block the receptor (Irvin and Carey, 
2008). For example, ER can be blocked using tamoxifen, which is the standard drug for 
treating honnone receptor positive breast tumors (Delozier, 201 0). Tamoxifen is an 
antagonist of the ER in breast tissue and will competitively bind to ER on tumors. 
Tamoxifen, therefore, decreases deoxyribonucleic acid (DNA) synthesis and inhibits the 
pro-tumor effects of estrogen (Jordan, 1993 ; Ali et al. , 2011 ) 
HER2 is a membrane bound receptor tyrosine kinase and is encoded by the proto-
oncogene HER2/neu. It is involved in signal pathways leading to cell growth and 
differentiation (Coussens et al. , 1985). HER2/neu is expressed in 20 - 30 % of invasive 
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breast cancer (Hudis, 2007). Overexpression of this receptor is generally associated with 
disease recUITence and a poor prognosis. Treatment of HER2+ tumors includes 
administering the humanized monoclonal antibody trastuzmaub (Ye et al., 1999). 
Trastuzmaub binds to the extracellular juxtamembrane HER2 domain and inhibits 
proliferation. As a result, HER2+ tumors regress (Hudis, 2007). 
Triple negative breast cancers have very low levels or no ER, PR or HER2/neu 
present on the tumor cells. It has a poor prognosis and requires more aggressive 
treatments, such as chemotherapy, radiation or surgery (Irvin and Carey, 2008). 
1.3. Immune Responses and Immune Profiling 
Transformed cells have the potential to proliferate and develop into a tumor. If a 
tumor is benign, the transformed cells are molecularly and functionally similar to nonnal 
cells (Lodish, et al. 2000). In contrast, malignant cells express some proteins 
characteristic of the normal cell, but these cells tend to grow and divide more rapidly. 
Malignant cells have the ability avoid detection by immune cells through altering immune 
recognition and manipulating immunosurveillance mechanisms (Lodish et al. , 2000; 
Mincheff, M, 2009). If the transfonned cells develop into a tumor, the immunogenic 
phenotype of the tumor can either facilitate tumor progression or regression. Clinical data 
suggest that immune profiles of patients with malignancies can be distinguished from 
immune profiles of healthy individuals. For example, a patient with a malignant tumor 
can have impaired T cell function and have activated suppressor cells and Treg cells fo und 
within circulation, the lymphoid organs and neoplastic tissues. These regulatory cells 
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have the potential to disable the tumor-killing cytotoxic T cells (CTLs) (Hrubisko et al. , 
20 10). 
An immune response mounted against a foreign element or antigen is initially 
broad and involves the innate immune system, which is followed by a more specific 
adaptive immune response. The innate immune response occurs rapidly upon exposure to 
the foreign antigen with phagocytic cells and inflammatory processes being acti vated. 
The adaptive immune response is slower and involves activation ofT and B cells, which 
express unique antigen specific receptors. For example, the T cell receptor (TCR) 
recognizes antigens in the context of the major histocompatibility complex (MHC) bound 
to an antigenic peptide. MHC class I molecules are recognized by CD8+ T cells and 
MHC class II molecules are recognized by CD4+ T cells (Mesquita eta!., 2010). As the 
focus of this thesis is on CD4+ T Hl7 cells, the next section will review antigen 
presentation by MHC class II molecules and antigen recognition by T cells. 
1.3.1. Major Histocompatibility Complex Class II 
MHC class II molecules, called HLA class II molecules in humans, are found on 
antigen presenting cells (APCs). Due to the enonnous number of antigens an individual 
encounters, HLA genes evolved to be highly polymorphic. HLA class II molecules 
(HLA-DR, -DP, or - DQ) are synthesized in the endoplasmic reticulum and are 
heterodimers, consisting of two peptide chains; a and ~- During synthesis of HLA class II 
molecules, the a and ~ chains complex with the invariant chain (li). Ii blocks the peptide 
binding groove of the HLA molecule to prevent premature peptide binding. The Ii also 
facilitates the export of the MHC class II molecules into the golgi and in the MHC class II 
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loading compartment (MIIC). Once in the golgi, Ii chain is cleaved into a truncated fom1 
known as class II-associated invariant chain peptide (CLIP). The M HC class II 
compartment (MIIC), containing the MHC class II molecule:CLIP complex, fuses with an 
endosome contai ning endocytosed and degraded antigens. CLIP is removed by a MHC 
class II-like structure, HLA-OM, which allows antigenic peptides to bind to the MHC 
class II molecule. The MHC Class II :peptide complex transits to the cell surface where 
the MHC molecule can interact with C04+ T cells (Figure 1.2). 
The HLA class II region is very complex due to polygenic and polymorphic 
nature of the HLA. The immunogenetics (IMGT)/HLA database has identified 7 ORA, 
1,150 ORB (1,051 ORB! , 1 ORB2, 57 ORB3, 15 ORB4, 19 ORBS, 3 ORB6, 2 ORB7, 1 
ORBS and 1 ORB9), 46 OQA 1, 160 OQB1 , 33 OPA l and 150 OPB1 alleles (HLA 
Nomenclature, 20 12). The genes that encode the a and p chains are designated A and 8 , 
respectively 
The polygenic nature of the MHC facilitates the binding of a range of peptides. 
The polymorphism refers to the variants of the genes within populations. In particular, 
the HLA-ORBI locus is extremely variable with 1,051 variants known to date. Generally 
the HLA-ORB1 variations are linked with additional structural HLA-ORB genes. For 
example, HLA-ORB 1 * 15 and 16 alleles associate with HLA-ORB5 alleles (old 
nomenclature: HLA-OR51 allele); HLA-ORB1 *04, 07 and 09 associate with HLA-ORB4 
(HLA-OR53); HLA-ORB1 *03, 11 , 12, 13 and 14 associate with HLA-ORB3 (HLA-
OR52); while HLA-ORB1 *01 , 10 and 08 are not associated with other HLA-ORB genes 
(Figure 1.3) (Campbell and Trowsdale, 1993). Therefore, due to the linkage of the ORB 
genes and co-dominant expression of HLA, an individual can express up to four different 
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CD4 T cel l 
Figure 1.2. MHC class !!:Antigenic peptide interaction. Antigen is endocytosed and 
degraded into peptides by the proteolytic environment in endosomes. The endosome, 
containing antigenic peptides, fuses with the MIIC. This compartment contains a MHC 
class II molecule (red) with a truncated form of the Ii, CLIP, bound to the binding groove. 
HLA-DM (purple) facilitates the removal of CLIP and the loading an antigenic peptide 
when the MIIC fuses with the endosome containing the antigenic peptides. The HLA 
class II molecules:peptide complex then moves towards the cell surface to present the 
antigen to a CD4 T cell (green). 
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DRj39 
DRS group 
DRj39 
"'08 
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DRj39 
'"15,"'16 DR 51 
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DR 
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"'04, "'07, *'09 DR 53 
Adapted from Campbell and Trowsdale, 1993 
Figure 1.3. HLA-DR alleles. 1-ll.,A-DR alleles grouped into 5 groups based upon the 
DRBIDRP genes. Pseudogenes are indicated by the colored boxes (light blue) (Campbell 
and Trowsdale, 1993). 
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HLA-DR allotypes . In addition to HLA-DR - HLA-DR associations, HLA-DR and 
HLA-DQ also have associated linkages. 
1.3.2. HLA Expression and Association with Disease 
As mentioned, HLA alleles are highly polymorphic and possess polymorphic 
peptide binding pockets that allow them to preferentially bind some peptides and present 
the peptides to T cell s to elicit a T cell response (Mesquita et al., 20 I 0). Therefore, 
depending on the HLA haplotypes an individual carries, an individual may differ in their 
response to pathogens. These differences in peptide binding due to allelic variants may 
predispose an individual to developing an autoimmune disease or carcinomas. 
Evidence from various studies suggests associations between carriage of particular 
HLA alleles and prominence of certain diseases or susceptibility to cancer. Type 1 
diabetes mellitus (TID) has been intensely studied for relationships with HLA molecules 
(Nerup et al. , 1974; Platz et al., 1981 ). Initial studies in Caucasians found links between 
increased susceptibility toT I D and HLA-88, HLA-815 (HLA-862) and HLA-B 18 (Platz 
et al. , 1981 ). Later studies revealed associations with HLA-DRB I *030 I (HLA-DR3), 
HLA-DR81 *04, HLA-DQ*0201 , HLA-DQ*0302 in patients with Tl D (Hirschhom, 
2003 ; Eisenbarth, 2003). Certain HLA alleles seem to associate with a genetic 
predisposition to other autoimmune diseases as well. For example, greater than 90% of 
ankylosing spondylitis patients carry HLA-827, suggesting that this allele may be 
necessary for the development of the disease. Alleles HLA-DQAl *0 102 and DQB*0602 
(DQ6) associate with a susceptibili ty to multiple sclerosis and narcolepsy, but seem to 
confer protection again Tl D. Rheumatoid arthritis also associates with several HLA-DR4 
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alleles (Thorsby and Lie, 2005). Recalling that MHC molecules are specific for particular 
peptides and T cell selection, an association between HLA allele presence and 
prominence of an autoimmune disease could indicate that tolerance to self-peptides is lost 
more frequently when that allele is present. This could suggest that HLA alleles interact 
with T cells in such a way that a self-peptide could be recognized as a foreign and an 
immune response would be mounted against the self. It could also mean that there is an 
association with another gene that is in linked disequilibrium with the patiicular HLA 
allele. 
In addition to association with autoimmune diseases, studies have found that 
certain HLA alleles associate with development of various types cancers. This is 
particularly true for virally associated cancers such as human papillomaviurus (HPV) 
(cervical cancer) and hepatitis B or C virus (heptacellular carcinoma) (Wallboomers eta!. , 
1999; Alison, et a!. 20 11). A study of 52 ovarian cancer patients and 239 healthy female 
controls found a significant increase in the frequencies of the haplotypes HLA-
DRB1 *0301, HLA-DQA1 *0501, HLA-DQB1 *020 1; and HLADRB*1001, HLA-
DQA 1 *0 I 0 I, HLA-DQB 1 *050 I in cancer patients (Kubler et a!. , 2006). A study by 
Chaudhuri et al. (2000) analyzed HLA associations in patients with early onset breast 
carcinoma as compared to healthy age-matched controls in an Ametican population in the 
Boston area. They reported that HLA-DQB*03032 and HLA-DRB I* 11 may be 
protective alleles against early onset breast cancer as these alleles were increased in 
healthy controls and decreased in patients with early onset breast cancer (Chaudhuri et a!. , 
2000). They also found that HLA-DRB3*02, a DR52 subtype, was increased in patients 
compared to healthy controls, suggesting that DRB3*02 can increase an individual's 
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susceptibility to breast cancer (Chaudhuri et a!. , 2000). A more recent study analyzing 
HLA associations between early onset Iranian breast cancer patients, compared to healthy 
age matched controls revealed that HLA-DQA1*030l and HLA-DRB1 *1303 were 
associated with higher incidences of breast cancer, whereas the alleles HLA-DQA I *0505 
and HLA-DRB I* 130 I were increased in healthy controls and decreased among breast 
cancer patients (Mahmoodi et a!, 20 II). Therefore, associations have been found to 
support the role of HLA haplotypes and risk for developing cancer and protection against 
cancer. However, not all CD4+ T cell responses are protective. Some studies have 
shown that CD4+ Treg cells associate with the suppression of the immune system, 
therefore conferring an advantage to the virus or cancer (Wraith et a!. , 2004). This 
concept will be discussed further in section 1.3 .3 . 
1.3.3. Effector and Regulatory CD4+ T cell Subsets in Humans 
As mentioned in section 1.3.1., MHC molecules are crucial for an adaptive 
immune response because MHC molecules present antigens to T cells. The presentation 
of foreign anti gens leads to their subsequent activation and differentiation. Following 
antigen recognition, CD4+ na·ive T cells di fferentiate into several effector cells, as 
summarized in Figure 1.4. Significant evidence indicates the existence of functionally 
unique C D4+ T cells based on expression of certain transcription facto rs and their profile 
of cytokine secretion. CD4+ T HI cells require the T box transcription factor (T -bet) and 
secrete the cytokines IFN-y, tumor necrosis factor (TNF)-a and IL-2. These cytokines 
promote cell-mediated immunity, phagocyte-dependent protective responses, mcrease 
antigen processing and up regulate expression of MHC class I and II molecules 
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CD4+T 
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STAT 5 
TGF-~ 
IL-10 
IL-4 
IL-13 
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IL-17a 
IL-17f 
IL- 10 
IL-35 
TGFj1 
Figure 1.4. Differentiation of naive CD4+ T cell into different effector subsets. A naive 
CD4+ which has encountered an antigen in the context of a MHC Class II molecule may 
differentiate into several effector cells depending on the cytokine milieu present. T H2 
cells require IL-4, STAT6 and GATA3 to differentiate. THl cells require STATl , 
STAT4, IL-12 and T-bet for differentiation. TH17 cells require IL-6, TGF-P, STAT3 and 
RORc2/yt for differentiation. Treg cells require STAT5, TGF-p, Il-LO and FOXP3 for 
differentiation. Items that are listed in the cell are transcription factors (ie: Gata3, T -bet), 
items that are colored and precede the T cell are required for the differentiation of the 
cell, and the items that are black and indicated by an arrow pointing right, in relation to 
the T cell, are cytokines produced by the cell (O'Shea and Paul, 2010). 
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(Romagnani, 2000). CD4+ T H2 cells require the transcription factor GAT A3 and secrete 
cytokines such as lL-4, IL-5, IL-6, IL-9, IL-10 and IL-13. Generally, TH2 associated 
cytokines cause T H l cell anergy and limit CTL proliferation but enhance humoral 
immunity, promote mast cell and eosinophil growth (Romagnani., 2000). CD4+ Treg 
cells dampen the immune response through secretion of IL-l 0 and transforming growth 
factor (TGF)-~. Treg cells inhibit T cell growth and macrophage activation. Recently, 
T H 17 cells have been identified as another CD4+ effector T cell. These cells produce IL-
17 (A-F), IL-6, IL-22 and IL-21 (Murugaiyan eta!., 2009; Weaver eta!., 2006; Bettelli et 
a!., 2008). As T H 17 cells are a major focus of this study, the function ofT H 17 cells will 
be reviewed in detail in the upcoming sections. 
1.3.4. Differentiation of N alve T Cells into T H 17 Cells 
For a na"ive T cell to differentiate into an effector T H 17 cells, the cytokines IL-6 
and TGF-~ are required. IL-6 preferentially activates single transducer and activators of 
transcription factor 3 (ST AT3) (Bettelli et a!., 2008). ST AT3 leads to the expression of 
retinoic orphan receptor C2/yt (RORc2/RORyt) (Bettelli et a!., 2008). RORc2 binds to 
the promoters of IL-17 and IL-2 1, leading to their transcription and translation (Bettelli et 
a!., 2008). IL-6 and IL-2 1 act in an autocrine manner and lead to the expression of 
ST A T3 in na·ive T cells. This favors further T H 17 differentiation as described. In 
addition to IL-6 and TGF-~, IL-23 is required for the commitment and stability of the 
T H 17 cell (Bettelli et a!., 2008). Once differentiated, a T H 17 cell, expresses IL-23R and 
IL-23 stabilizes the TH17 phenotype (Murugaiyan eta!., 2009). IL-l~ is also reported to 
cause expansion of memory T H 17 cells in patients with psoriasis (Kryczek et a!., 2009). 
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In tenns of tissue homing molecules, T H 17 cells have been reporied to express 
high levels of CXC chemokine receptor 4 (CXCR4), CC-chemokine receptor 6 (CCR6), 
several CD49 and the C type lectin receptor CD161 (Zou and Restifo, 2010, Yamazakiet 
at. , 2008; Boisvert et at. , 201 0). CXCR4 is specific for the stromal cell-derived factor 1 
(SDF-1) or CXC chemokine ligand 12 (CXCL12) and CD4+ T cells migrate towards this 
ligand. Generally, CXCL12 is found in bone marrow and tumors (Kryczek et at. , 2007) 
and as a result, CD4+ T cells home towards bone marrow and tumors. The presence of 
CCR6 results in migration towards CC-motif ligand 20 (CCL20), which is expressed by 
tissues (i.e. liver, appendix, lymph node and Peyer' s patch) and cells (peripheral blood 
mononuclear cells (PBMCs), epithelial cells) (Ito et at., 2011). The role of CD161 on 
T H 17 cells is currently unknown (Kesselring et at. , 2011 ). The absence of markers of 
lymphoid migration, CCR 7 and CD62L, suggest that T H 17 cells do not migrate to 
lymphoid tissues. 
With respect to other cell markers, conventional T cell molecules have not been 
detected on T H 17 cells. For example, HLA-DR, found on CD4+ T HI , T H2 and Treg cells, 
is not expressed by T H 17 cells. CD25, a surface molecule found on activated T cells is 
not present on T H 17 cells. Granzyme 8 , located in the granules of CTL and NKT cells, is 
not found in T H 17 cells. Immunosuppression markers, such as programmed cell death 1 
(PD-1), expressed on activated T cells, and FOXP3 are not present on T H 17 cells either. 
Therefore, it would appear that T H 17 cells are distinct from the other T cell subsets (Zou 
and Restifo, 20 1 0). 
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1.3.4.1. Interaction ofT H17 Cells with Other CD4+ T Cell Subsets 
As described in section 1.3.4. and presented in Figure 1.4., TGF-P is required fo r 
the differentiation of FOXP3+CD4+ Trcg cell and T H 17 cells (O'Shea and Paul, 201 0). It 
has been suggested that although TGF-P supports Treg cell differentiation, simultaneous 
stimulation of naive T cells with IL-6 and TGF-P promotes T H 17 cell differentiation and 
suppresses Trcg differentiation (Bettelli et al. , 2006; Pan et al. , 20 II ). This is further 
supported by the identification of T cells, in both mice and humans, which express both 
R0Rc2 and FOXP3, the transcriptional regulators for T H 17 cells and Trcg cells, 
respectively (Zhou et al. , 2009; Yang et al. , 2008). Depending on the cytokine milieu 
present, it appears that one transcription factor will dominate the other. For example, 
higher levels ofTGF-P favor FOXP3 expression and repress IL-23 R expression, which is 
required for T H 17 cell maintenance (Zhou et al., 2009; Yang et al. , 2008). Once 
expressed, FOXP3 can also bind to R0Rc2 and antagonize the T H 17 transcription factor. 
On the other hand, if pro-inflammatory cytokines are present, such as IL-21 and IL-6, 
these cytokines will activate STAT3 and overcome the FOXP3 mediated inhibition of 
RORc2 (Zhou et al., 2009; Yang et al. , 2008). The pro-inflammatory environment will 
favor T H 17 cell differenti ation (Zhou et a!. , 2009; Yang et al. , 2008). 
Studies have also been conducted to determine ifTH1 7 cells interact with THl /TH2 
subsets. Although, some IL-1 7 producing CD4+ T cells in humans were found to secrete 
small amounts of IFN-y (Kryczek et al. , 2009). IFN-y, tends to inhibit the induction of 
IL- 17. Further a member of the [L-1 2 cytokine family, IL-27, promotes expression of the 
T H1 transcription factor, T-bet, but inhibits TH1 7 cell differentiation in a STAT! 
dependent manner (Zhou et a!., 2009; Dong, 2011 ). In experiments conducted in mice, 
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in vitro generated T H 17 cells can convert to T H 1 cells in lymphopenic environments (Lee 
et al., 2009; Matiin-Orozco et al., 2009), suggesting plasticity exists between these two 
helper T cell groups. Similarly, IL-4, a cytokine required for the differentiation of 
GATA3 T H2 cells activates growth factor independent 1 (GFI-1 ), which is reported to 
inhibit both T H 17 and Trcg cell differentiation (Zhou et al., 2009). 
1.3.5. T H 17 Cytokine Profile and the Biological Function ofT H 17 cells. 
In the years following the identification and classification of CD4+ T H 17 cells, an 
abundance of research concerning their biological function has been conducted. T H 17 
cells were originally defined by their production of IL-17 cytokines, previously termed 
CTLA (cytolytic T lymphocyte antigen)-8 cytokines (Harrington et al. , 2006). There are 
6 types of IL-17: IL-17 A-F. T H 17 cells primarily produce IL-17 A and IL-17F, which are 
functionally similar because they induce the production of proinflammatory cytokines, 
chemokines and metalloprotenases by cells and tissues that express IL-l7R (Bettelli et al. , 
2008). IL-17 A is generally produced 4 - 8 hours following a microbial infection and 
enhances neutrophil chemotaxis, granulocyte colony stimulating factor (G-CSF) and 
CXCL8 (Happel et al. , 2005; Cua and Tato, 201 0). However, it was previously thought 
that T H 17 cells were the sole producers of I L-17. Yet, recent research suggests that y8 T 
cells, invariant natural killer (iNK) T cells, NK cells, neutrophils, macrophages, 
eosinophils and some myeloid cells can produce IL- 17 cytokines (Cua and Tato, 20 I 0; 
DeNardo and Coussens, 2007). 
Along with the secretion of IL-1 7, T H 17 cells have been shown to secrete IL-22, 
which is a member of the IL- l 0 family of cytokines and is a mediator of cellular 
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inflammatory responses. IL-22 initiates innate immune responses against bacterial 
pathogens, especially in epithelial cells. IL-22 can also induce ~-defensins in epithelial 
cells and promote psoriasis (Zheng et a!., 2007; Liang et a!. , 2006). Differentiated T H 17 
cells also secrete IL-21 , which acts in an autocrine manner by activating STAT3 and 
leading to the amplification ofT H 17 cells as previously described in Section 1.3. IL-21 
further supports B cell differentiation and antibody class switching (Spolski et a!., 2008). 
Together, IL-17 and IL-21 promote inflammation. Therefore, it is not a surprise 
that T H 17 cells have a role in autoimmune disease. Overexpression of IL-17 is associated 
with a variety of inflammatory diseases, such as rheumatoid arthritis, systemic lupus 
erthematosus and asthma (Bettelli et al. , 2008). A key study that illustrated the role of 
T Hl7 cells in autoimmunity was performed on mice deficient in IL-1 2p40 subunit, part of 
the IL-23R (Bettelli et al., 2008). As IL-23 is required for the maintenance of the T H 17 
phenotype, without a functioning receptor for IL-23, there would be no functioning T H 17 
cells. Mice that had this deficiency were found to have lower levels of T H 17 and were 
protected from experimental autoimmune encephalomyelitis (EAE) and collagen induced 
arthritis. It was therefore concluded that T H 17 cells could induce autoimmunity through 
tissue inflammation and activation of the innate immune system (Bettelli et a!. , 2008; 
Dong et a!., 2008). The association between T H 17 cytokines and autoimmunity has been 
studied more in depth than the association between these cytokines and promotion or 
protection from cancer. 
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1.4. Immune Response and Cancer 
The immune system plays a dual role in cancer. Through destroying cancer cells or 
inhibiting their growth, the immune system can suppress tumor growth. However, 
through recruiting certain cells, such as Treg cells, and establishing a patiicular 
microenvironment, the immune system may facilitate and promote tumor growth. This 
section will explore the immune system 's ability to act in a pro-tumor and anti-tumor 
manner (Schreiber et a!. , 20 11 ). 
1.4.1. Anti-tumor Immune Responses 
An anti-tumor immune response can involve both components of the innate and 
adaptive immune system. Type 1 lFNs, components of the innate immune system, may be 
present within a tumor environment, potentially produced from CD 11 c + dendritic cells 
(Diamond et a!., 20 11 ). Type l IFNs activate other dendritic cells, which engulf tumor 
antigens to promote an anti-tumor immune response (Matzinger, 1994; Schreiber et a!., 
2011 ). Type l lFNs also increase NK cell activity and subsequently increase CTL kill ing 
of tumor cells. Type I IFNs also have the ability to induce growth inhibition and death of 
cancer cells (Trinchieri, 20 1 0). Damage-associated molecular pattern molecules 
(DAMPs) can be released from dying tumor cells. In particular, high mobility group box 
(HMGB) l , a DAMP, may be recognized by toll like receptor (TLR) 4 on dendritic cells 
and facilitate an anti-tumor response (Sims, 20 I 0) 
Although these elements of the innate immune system assist in protection against 
tumor development, an adaptive immune response is needed to protect the host against a 
developing tumor. Most tumors cells are positive for MHC class I. CD8+ T cells or CTLs 
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may recognize tumor antigens presented in the context of MHC class I and induce tumor 
killing (Yu and Fu, 2006). The ability of CDS+ T cells to act as effectors against tumors 
is further supported by clinical data. A recent study conducted by Mahmoud et al. (20 ll) 
on 1334 breast tumors analyzed the infiltrating CDS+ T cell populations by 
immunohistochemistry. This study found significant correlations between the total 
number of COS+ T cells and the number of distant stromal COS+ T cells and increased 
patient survival (Mahmoud et al., 2011 ). 
C04+ T H l cells also assist in the activation of CTLs. T H l cells interact with APCs 
and cause APCs to express inter-cellular adhesion molecule (I CAM) l , COSO and CD86 
or promote IL-12 secretion from the APCs. These factors are essential for more effici ent 
CTL activation (Yu and Fu, 2006). T H 1 cells also secrete cytokines, such as IFN-y, which 
promote up-regulation of MHC molecules. This can improve tumor associated antigen 
presentation (Yu and Fu, 2006). 
Whether or not T H 17 cells have a pro-tumor or anti-tumor role is debatable. T H 17 
cells may recruit dendritic cells to tumor sites and promote activation of tumor specific 
CTL (Bronte, 200S). A model which suggests that T H 17 cells promote an anti-tumor 
response within a tumor microenvironment, is based on the abi lity of IL-17, in the 
presence of IFN-y, to promote the secretion of CXCL9 and CXCLl 0 from tumor cells. 
Both CXCL9 and CXCLl 0 are ligands that attract CXCR3+ NK cells and CTLs. 
Therefore, the production ofboth CXCL9 and CXCLlO can lead to the migration ofNK 
cells and CTLs to the tumor microenvironment and lead to cytolytic killing of tumor cells 
(Figure 1.5.) (Maniati et al. ,20 1 0). CCL20, secreted by T H 17 cells, can attract dendritic 
cells to the tumor microenvironment due to the presence of CCR6 on dendritic cells. The 
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dendritic cells can engulf tumor antigens and present these antigens to C D4+ or CDS+ T 
cells, leading to a specific immune response against the tumor (Figure 1.5.) (Maniati, et 
al.,201 0). 
1.4.2. Pro-tumor Immune Responses 
Section 1.4. 1. detailed potential anti -tumor roles of the adaptive immune system. 
However, there is evidence to suggest that elements of the adaptive immune system 
promote tumor growth. For example, T H2 cells faci litate antibody production and can 
sway immunity away from beneficial cellular mediated responses. T H2 cells, through 
secretion of IL-4, can enhance pro-metastatic EGF receptor signaling profiles in 
malignant cells, therefore promoting tumor growth (DeNardo et al., 2009). 
C D4+C D25+FOXP3+ T cells (Trcg cells), enriched wi th CTLA-4 and g lucocorticoid 
induced tumor necrosis factor receptor fami ly related gene, are considered to suppress 
anti-tumor behavior from cells such as T H 1 cells (Watanabe et al. , 20 I 0; Ostrand-
Rosenberg, 2008). There are several studies that support the concept that Treg cells 
suppress anti-tumor behaviors of other cells. For example, Liu et al. (2011) examined 
1270 invasive breast carcinomas by IHC for infiltrating Trcg cells. They found high 
densities of Trcg cells associated with poor prognostic indicators such as ER and PR 
negative tumors, high histological grades and HER2 overexpression. Further, high Trcg 
cell populations co1Telated with decreased overall survival and recurrence free survival 
(RFS) (Liu et al. , 201 1) 
The anti-tumor effects of T H 17 cells were previously discussed in Section 1.4.1. 
However, models and studies exist to support the hypothesis that T H 17 cells support 
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Figure 1.5. Anti-tumor effects of TH17 cells. ll.,-17 and IFN-y work together and 
stimulate tumor cells to release the chemokines CXCL9 and CXCL 10, which recruit NK 
cells and CTLs to the tumor environment. This can lead to cytolytic killing of the tumor 
cells. TH17 cells also release CCL20, a chemoattractant for dendrtic cells. Dendritic cells 
take up tumor antigens and lead to an immune response against the tumor antigen. 
Adapted from Maniati et al2010 (Maniati et al., 2010). 
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tumor growth as well. The exact mechanism by which inflammation promotes metastasis 
is unclear, but it is likely through the production of TL-1 7. IL-17 induces vascular 
endothelial growth factor (VEGF) secretion from endothelial, stromal and tumor cells. 
VEGF acts in an autocrine manner to promote secretion of TGF-~ and IL-6. The 
combination of TGF-~ and IL-6 forms a positive feedback loop, leading to more T H 17 
cell differentiation. This could promote chronic inflammation leading to metastasis 
(Murugaiyan et al. , 2009). IL- 17 can support the production of several chemokines, 
CXCLl /CXCL2 and these chemokines recruit neutrophils. In the presence of IL-1 7, 
neutrophils secrete inflammatory proteinases, thereby contributing to promotion of 
inflammation in the tumor microenvironment. Furthermore, IL-17 promotes CXCL-8 
production from stromal and epithelial cells. CXCL-8 promotes angiogenesis, which is 
the process of growing new blood vessels from existing blood vessels. By creating new 
blood vessels, angiogenesis allows nutrients and oxygen to reach a tumor mass, thereby 
facilitating growth (DeNardo et al., 2007; Maniati et al. , 201 0). Figure 1.6. summarizes 
the pro-tumor role ofT H 17 cells. As the role ofT H 17 cells as either mediators of tumor 
growth or suppression is controversial, the next section will summarize results from 
several clinical studies. 
1.5. Studies ofTH17 Cells Within Tumor Microenvironments 
The following Sections 1.5. 1-1 .5.2. review studies that have analyzed tumor 
infiltrating and peripheral populations ofT H 17 cells in cancers that are associated with 
chronic inflammation (Section 1.5.1.) and honnones (Section 1.5.2.). Several cancers 
have been linked to chronic inflammation and understanding ifT H 17 cells have a role in 
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Figure 1.6. Pro-tumor effects of TH17 cells. ll.--17 can have direct effects on 
angiogenesis by acting upon endothelial cells and causing the secretion of VEGF. VEGF 
leads to the production of TGF-~ and ll.--6 from endothelial cells, which can act together 
to cause the differentiation of more naive T cells into T H 17 cells. Malignant cells and 
tumor associated macrophages also secrete ll.--6. ll.--17 also promotes the secretion of 
CXCL1 and CXCL2 from the endothelial cells and these recruit neutrophils. Due to the 
ll.--17 present in the tumor microenvironment, the neutrophils will produce inflammatory 
proteinases. This could produce a state of chronic inflammation and promote metastases 
of the tumor cells. Endothelial cells also secrete CXCL8 in the presence of ll.--17 and 
CXCL8 can promote angiogenesis. Adapted from Maniati et al. 2010 
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such inflammatory cancers could provide new therapies. Furthem1ore, as breast cancer 
progression and treatment is strongly influenced by the hormones estrogen and 
progesterone, it is beneficial to analyze the role ofT H 17 cells in other cancers influenced 
by steroid honnones. 
1.5.1. T H17 Cells in Cancers Associated with Chronic Inflammation 
A substantial number of studies have supported the notion that chronic 
inflammation can predispose an individual to cancer. For example, there is association 
between chronic inflammatory bowel diseases and the increased risk of colon carcinoma 
(Ullman, et a!. 2011 ). Gastric (Zhang et a!., 2008; Maruyama et a!., 201 0), 
hepatocellular, (Zhang et a!., 2006), colorectal (Liu et a!., 201 1 ), uterine cervical (Zhang 
et a!., 20 11) and lung cancers (Provinciali et a!., 201 1) have associations with chronic 
inflammation and studies have been conducted on these cancers to detennine if 
associations with T H 17 cells and patient outcome exist. 
1.5.1.1. T H 17 Cells in Gastric Cancer 
Helicobacter pylori infection leads to the induction of chronic inflammation in the 
gastric mucosa. Changes in the gastric mucosa can lead to changes in gastric hormone 
release and disruption of neural pathways that contribute to the secretion of gastric acid. 
If gastric acid secretion is impaired or increased, the phenotype of gastritis may change. 
If the corpus atrophies, the secretion of essential substances, such as hydrochloric acid 
and pepsin, is impaired. When such atrophy occurs, these patients carry the highest risk 
for developing gastric cancer (Marteau et al. , 20 11 ). Zhang et al. (2008) analyzed 
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PBMCs, tumor draining lymph nodes and tumor tissue from 53 gastric cancer patients. 
Thirteen of the 53 patients had stage I gastric cancer, while the other 40 patients had more 
advanced stages. The Zhang et al. (2003) study observed an increase in PBMC 
population ofT 1-1 17 cells with disease progression. The population ofT 1-117 cells in the 
tumor draining lymph nodes also increased with disease progression. Although the 
number of patients in this study was small , they observed a positive cotTelation between 
the number of T 1-117 cells in circulation and in tumor draining lymph nodes, and 
progression of gastric cancer, suggesting a potential pro-tumor role ofT 1-1 17 cells (Zhang 
et a!. , 2008). 
A later study analyzed populations of tumor infiltrating lymphocytes (T ILs) and 
PBMCs in 55 gastric cancer patients (Maruyama et a!., 201 0). Twenty-seven patients had 
stage I disease and 28 had advanced stage disease. Flow cytometric methods were 
employed to analyze the peripheral blood lymphocytes (PBLs) and IHC methods were 
used to analyze paraffin embedded tissue. Flow cytometry revealed that PBMC T 1-11 7 cell 
frequency (identified by IL-1 7 positive/CD4 positive cells) was lower in advanced staged 
cancer than in comparable healthy donor PBMC. Upon stimulating isolated T 1-11 7 cells 
from gastric cancer with anti-CD3 and anti-CD28, the cytokines IL-1 7, IL-2 1 and IL-23 
were produced. IHC staining of tumor lesions revealed that T 1-1 17 cells significantly 
decreased with progressing stages. This study further noted that the ratio ofT 1-1 17 IT reg 
cells was significantly higher in earl ier stage disease and decreased with progressing 
stages. This study, in contrast to Zhang et al (2003), suggests that T 1-1 17 cells did not have 
a pro-tumor role in gasttic cancer as the populations decreased with advancing cancer 
(Maruyama et al. , 20 I 0). Since these two studies produced conflicting resul ts and in both 
30 
studies only small numbers of patients were investigated, it is unclear whether T H 17 cells 
are beneficial or not to gastric cancer patients. 
1.5.1.2. T H17 Cells in Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) frequently develops in livers of patients infected 
with hepatotropic viruses (Hepatitis B virus (HBV) and Hepatitis C virus (HCV)), high 
levels of toxins (alcohol hi-products), or metabolic liver diseases. All of these conditions 
promote chronic inflammation within the liver (Alison et al., 2011 ) . Zhang et al. (2006) 
characterized IL-1 7 producing cells in HCC and determined if the presence of these cells 
had prognostic value. To study the distribution ofiL-17 producing cells, PBLs and TILs 
were collected and levels of IL-1 7 producing cells were determined by flow cytometry. 
TILs had the highest population of IL-17 producing cells. They also observed that 20-
40% of tumor and non-tumor (from healthy donors) IL-1 7 producing cells were not CD4+ 
cells, suggesting another cell was producing IL-1 7. Next, Zhang et a!. (2006) 
characterized tumor infiltrating T H 17 cells and observed that almost half of these cells 
could produce IFN-y and IL-17 together. IL-1 7 producing cells in the PBLs population 
did not produce IFN-y simultaneously with IL-17. This is suggestive of a functional or 
development relationship between T H 1 and T H 17 cells within hepatocellular tumor 
environments. IHC and confocal microscopy were used to visualize IL-1 7 producing 
cells within tumor environments. They observed that not all IL-1 7 producing cells were 
CD4+ cells, therefore confirming the flow cytometry data. The Zhang et al. (2006) also 
reported that CD4+ producing IL-17 cells expressed CD45RO, CCR4 and CCR6 but not 
CD62L or CCR 7. These results are similar to the study by Kryczek et a!. (2009) on 
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ovanan cancer, described in Section 1.5.2.1 (Kryczek et a!., 2009). With regards to 
overall survival, patients with increased intratumoral levels of IL-17 had shorter overall 
survival (OS) and RFS. Based on the observations of this study, higher levels of 
T H 17 /IL-17 producing cells appear to be a poor prognostic indicator for hepatocellular 
cancer patients (Zhang et a!. , 2009). 
1.5.1.3. T H 17 Cells in Colo rectal Cancer 
As with the case of gastric cancer, chronic inflammation is also linked to the 
developmental of colorectal cancer (CRC). Liu et a!. (20 11) studied 52 patients with 
CRC stage Ill. CRC sections were stained for IL-1 7 using IHC techniques. Although 
non-tumor adenoma had positive IL-17 staining, the peritumor, and more so in the 
intratumor region, had more concentrated staining. Dual staining confocal microscopy 
showed that both CD4 cells (T H 17 cells) and CD68 (macrophages) cells were producing 
IL-17. IL-17 was found to be an independent predictor of overall survival, as high IL-17 
levels had statistically significant lower 5-year survival and decreased RFS. Based on 
this study, it would appear that IL-1 7 negatively impacts patients with CRC (Liu et a!. , 
2011). 
Another study by Tosolini eta!. (2011) analyzed the balance between cytotoxic T 
cells and different subsets of helper T cells in 125 frozen colorectal tumor specimens. 
T H 17 cells were analyzed by mRNA levels of RORc and IL-17 A. Through real-time 
PCR, this study identified increased IL-1 7 A in colorectal cancer tissues when compared 
to adj acent normal mucosa. Furthermore, upon defining three T H 17 categories (low, 
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heterogenous and high based on mRNA IL-17 A and RORc levels), the T Hl711i category 
cotTesponded to a poor overall survival. In particular, when analyzing T H 17 categories in 
relation to profiles developed for T H l , the T H 1711i/T H 110 combination had the worst disease 
free survival determined by Kaplan-Meier (p=0.005). This study would suggest that 
T H 17 cells within a colorectal tumor environment have a negative impact on the patient, 
similar to the results found by Liu et al. (20 ll ) and Tosolini et al. (20 ll ). 
1.5.1.4. T H 17 Cells in Uterine Cervical Cancer 
HPV is the most important etiological agent of cervical cancer. A report in 1999, 
cited as high as 93% of invasive cervical cancers contain replicating HPV (Walboomers 
et a!., 1999). When a host is infected with HPV, the inflammatory response can promote 
lesion progression and affect potential tumor development by involving inflammatory 
channels and cells (Boccardo, 20 1 0). Zhang et al. (20 11 ) examined the expression of IL-
17, FOXP3 and IL-l 0 in uterine cervical cancer (UCC), cervical intraepithelial neoplasia 
(CIN) and healthy donors PBL using flow cytometry and enzyme linked immunosorbent 
assays. IL-1 7 producing CD4+ T cells were classified as T H 17 cells and 
CD4+CD25+FOXP3+ cells were classified as Treg cells. Levels of peripheral blood T H 17 
cells were significantly increased in UCC and CIN patients as compared to healthy 
controls. T H 17 cell frequency also positively correlated with lymph node metastases and 
vaso-mvaswn. Similarly, Tn.:g cells were increased in untreated UCC patients as 
compared to CIN patients and healthy donors. This increase in Treg cells was not 
observed in CIN or healthy donor peripheral blood. Up-regulation of both Treg and T H 17 
cells in UCC suggests that both cell types may be involved in the progression or 
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development of the disease. Moreover, the link between T H 17 cells and metastases would 
suggest that T H 17 are not beneficial to cervical cancer patients (Zhang et al. , 20 II). 
1.5.1.5. TH17 Cells in Lung Cancer 
Inhaling cigarette smoke, as well as chimney smoke and forest fire smoke, irritates 
the lung tissue and leads to an inflammatory response to eliminate the foreign 
toxin/chemical. If this response is repetitive, as in the case of addicted cigarette smokers, 
chronic inflammation develops within the lungs. The link between smoking cigarettes 
and cancer has been well established, but whether or not inflammatory cells, such as T H 17 
cells have a role in the promotion of cancer is less clear (Provinciali et al., 2011 ). Koyama 
et a!. (2008) analyzed peripheral blood T cell populations in 35 small cell lung cancer 
(SCLC) patients, 8 long tenn survivors of SCLC and 19 healthy donors. Those patients 
that lacked detectable distant metastases and had tumors confined to hemithorax (half of 
the thorax) and mediastinum (non-dilineated structures in the thorax) were defined as 
limited stage disease (LD) SCLC and those patients that had prominent distant metastases 
were referred to as extended stage disease ED- SCLC. Flow cytometric methods were 
used to isolate and analyze PBMCs. The overall percentages of CD4+ T cells did not 
differ among healthy donors, LD-SCLC and ED-SCLC. However, CD62LhighCD4+ Trcg 
cells were increased in ED-SCLC, as compared to healthy donors. CD4+ T cells were 
sorted by flow cytometry and stimulated with anti-CD3 and cytokine production was 
analyzed. The study found that CD62L10wCD4+ cells produced TH l , TH2 and TH17 
cytokines. Furthenn ore, IL-17 A production was significantly up-regulated in LD-SCLC 
as compared to healthy donors and ED-SCLC. Based on these observations, IL-1 7 
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producing cells were increased in LD-SCLC and seemed to be beneficial to the patient 
(Koyama et al., 2008). 
1.5.1.6. Summary ofTH17 Cells in Cancers with Associated Chronic Inflammation 
The link between prevalence of inflammation and development of cancers in tissues 
ts still being studied. However, based on the studies summarized in Section 1.5.1., 
increased frequency of T H 17 cells/IL-1 7 producing cells is often associated with 
decreased RFS, OS and poor prognostic indicators. The two gastric studies mentioned 
yielded conflicting results: the most recent by Maruyama et al. (20 1 0), suggests that T H 17 
cells slow cancer development and progression, whereas the Zhang et a!. study (2008) 
suggested T H 17 cells have a pro-tumor role. In both HCC and CRC, increased levels of 
IL-17 correlate with decreased RFS and OS. Increased levels of T H 17 cells in UCC 
patients were associated with disease progression. However, in the case of small cell lung 
cancer, higher levels IL- 17 producing cells in the peripheral blood seemed to associate 
with limited stage disease, a better prognosis than extended stage disease. It should be 
noted that a caveat of these studies is the small number of patients and studies examined. 
Furthennore, some studies focused on circulating T H 17 cells, rather than tumor 
infiltrating T H 17 cells, which may provide inaccurate representations of the tumor milieu. 
Yet, overall , there seems to be a trend for higher IL-17 levels or T H l 7 cells to promote 
tumor growth in tissues that are frequently inflamed. 
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1.5.2. TH17 Cells in Cancers Influenced by Hormones 
As the development of cancer is influenced by inflammation, exposure to 
hormones, such as estrogen, progesterone and testosterone, may influence the growth of 
tumors. As ovarian, breast and prostate cancer cells frequently express hormone 
receptors, these cancer cells may proliferate due to exposure to honnones. 
1.5.2.1 T H 17 Cells in Ovarian Cancer 
As discussed in Section 1.2.1., breast cancer cells expressing ER and PR proliferate 
when exposed to either steroid honnone. Ovarian cancer cells multiply as a result of 
ER/PR as well (Ahmad and Kumar, 2011). In 2008, Miyahara et al. analyzed peripheral 
blood, ascitic fluid and tumor specimens from ovarian cancer patients for T H 17 type 
cytokines. The tumor environment contained the cytokine milieu necessary for the 
differentiation and expansion ofT H 17 cells. Further, this study determined that T H 17 cell 
populations were increased in ovarian cancer tissue as compared to peripheral blood 
populations (Miyahara et a!., 2008). Another study on ovarian cancer, conducted by 
Kryczek et al. (2009), analyzed the presence ofT H 17 cells and their clinical significance 
in 20 1 ovarian cancer patients. This study focused on the characterization and evaluation 
of the distribution and phenotype ofT H 17 cells in tumor environments. Similar levels of 
T H 17 cells were found in tumor draining lymph nodes of cancer patients, cancer patient 
peripheral blood and health donor peripheral blood. Evaluation of the phenotype revealed 
that tumor infiltrating T H 17 cells expressed CD4, CXCR4, CCR6, CD61 , CD49c, CD49d 
and CD49e which suggest that T H 17 cells could migrate and be retained within a tumor 
microenvironment. HLA-DR, CD25, CCR2, CCR5 and CCR7 were not expressed by the 
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tumor infiltrating T H 17 cells. With respect to the cytokine profile of the tumor 
infiltrating T H 17 cells, significant amounts of IL-17, IFN-y, TN F-a and I L-2 were found. 
This cytokine profile was observed in five other types of cancer studied: colon cancer, 
HCC, pancreatic cancer, melanoma and renal cancer (Kryczek et al. , 2009). The Kryczek 
et al. study (2009) investigated the mechanism of induction of T H 17 cells within the 
ovarian cancer tumors. It was found that plasmacytoid dendritic cells (DCs) had minimal 
effect on T H 17 induction but tumor-associated macrophages (TAMs) and myeloid DCs 
could stimulate the induction ofT H 17 cells from memory T cells, but not nai·ve T cells. 
The mechanism behind the induction ofT H 17 cells by TAMs was thought to be through 
the production of IL-l~' which is reported to play a role in expanding memory T cell 
populations into T H 17 (Kryczek et al. , 2009). Further analysis revealed a correlation 
between higher levels of IL-17, CXCL9 and CXCLIO in ovarian cancer ascites. Both 
CXCL9 and CXCLI 0 are involved in T H 1 cell recruitment, suggesting T H 17 cells support 
an anti-tumor response. Lastly, Kryczek et al. (2009) found a significant relationship 
between improved patient outcome and T1-1 17 cells, which suggests that T H 17 cells are 
antagonizing the tumor, favoring the theory that T H 17 cells have an anti-tumor role 
(Kryczek et al. , 2009). 
A more recent study in 2012 investigated peripheral blood and epithelial ovarian 
cancer specimens from 44 patients undergoing cytoreductive surgery in Prague (Fialova 
et al. , 2012). TH17 lymphocytes (detennined through flow cytometry, based on presence 
of IL-1 7 A) were detected in l 00% of the ovarian tumor samples and the proportion of 
T H 17 cells within the CD4+ T cell subset was higher in patients wi th limited stage disease. 
The frequency ofT H 17 cells within the peripheral blood was not predictive of the number 
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ofT H 17 cells within the tumor (Fialova et a!., 20 12). Therefore, this recent study seems 
to support the findings of Kryczek et a!. (2009): that T H 17 cells may have an anti-tumor 
role in ovarian cancer. 
1.5.2.2. T 1-1 17 cells in Prostate Cancer Patients 
S.fanos et al. (2008) studied prostate infiltrating lymphocytes (P IL) in 20 patients 
with prostate cancer. CD4+ T cells were isolated from the PILs and analyzed by flow 
cytometry to determine the frequencies ofT cell subsets present. Upon stimulation of 
CD4+ T cells with phorbol 12-myristate 13-acetate (PMA) and ionomycin, a significant 
skewing towards T H 17 cells (IL-17 producing/CD4+ T cells) in the PIL population was 
observed. They suggest the frequency of T H 17 cells in the PI L may be due to the 
presence of both TG F -~ and IL-6 in the tumor. S.fcmos et al. (2008) also noted that there 
was an inverse relationship among Trcg and T H 17 cells, ie. when T H 17 cells were present 
in higher relative amounts, there were less Trcg cells present. With respect to T H 17 cell 
population and prognostic indicators, there was an inverse relationship between T H 17 
cells skewing and Gleason tumor grade, suggesting a potential anti-tumor role for T H 17 
cells (Sfanos et al., 2008). 
1.5.2.3. T 1-117 cells in Breast Carcinoma Patients 
The effect of estrogen and progesterone on breast cancer cells has been previously 
discussed in Section 1.2.1 . Horlock et a!. (2009) studied the effects of trastuzumab on 
T H 17 cell and Trcg cell populations in the peripheral blood of 34 breast cancer patients, 27 
of which were HER2+. Peripheral blood from healthy donors was used as a control. 
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Patients with HER2+ breast cancer were treated with trastuzumab and samples were taken 
before, during and after treatment. Trcg cells, identified by FOXP3 and CD25, were 
significantly higher in breast cancer patients, regardless of HER2 status in comparison to 
healthy controls. There was no significant difference in Treg frequency between HER2+ 
and HER2neg patients. Following treatment of HER2+ patients with trastuzumab, the Treg 
population in the peripheral blood decreased. This observation suggests that Treg cells aid 
in tumor progression as treatment reduces their numbers. With respect to T H 1 7 cells, 
healthy donors and HER neg patients had similar numbers ofT H 17 cells. However, HER2+ 
patients had increased peripheral T H 17 cells in comparison to HER2neg and healthy 
donors. Following treatment of HER2+ patients with trastuzumab, the levels of T H 17 
cells increased. Furthermore, analyze of the ratio of Trcg:T H 17 cells in peripheral blood 
revealed that HER2+ patients had a significantly higher ratio than HER2ncg patients and 
healthy controls. There was no significant difference in the ratio between HER2neg 
patients and healthy controls. This study suggests an anti-tumor role fo r T H 17 cells and 
suppotis the concept that T H 17 cell s and Tn;g cells are inversely related (Horlock, et a!. 
2009). 
In 20 12, Yang et al. (20 12) studied 30 breast cancer patients. In particular, they 
analyzed the TlL population for TH 17 cells. It was found that there were increased IL-1 7 
positive cells in cancerous tissue as compared to nonnal breast tissue (both evaluated by 
flow cytometry and IHC methods). The frequency ofT H 17 cells was also proportional to 
the amount of IL-6, TG F-P and [L- IP in the tumor sample. When Yang et al. (20 12) 
compared the frequency of T H1 7 cells to prognostic indicators, there were negative 
associations between TNM stage, blood vessel invasion and increased numbers of 
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metastatic lymph nodes. However, there was no correlation with the frequency of Treg 
cells. Therefore, Yang's study supports the notion that T H 17 cells have an anti-tumor role 
(Yang eta!., 2012). 
1.5.2.4. Summary ofT H 17 Cells in Cancers Influenced by Hormones 
In each of the hOLmonal cancers discussed, T H 17 cells were associated with 
improved outcomes and prognoses, suggesting T H 17 cells have an anti-tumor role in these 
honnonally influenced cancers. 
The previous Sections 1.5.1 and 1.5.2, chronicled studies of T H 17 cells within 
tumor microenvironments. However, due to the outcomes of these studies, it is difficult 
to deduce the role ofT H 17 cells within tumor microenvironments. It is quite possible that 
T H 17 cells cannot be generalized as either pro-tumor or anti-tumor but the role ofT H 17 
cells is dependent upon the cancer type, location, stage of cancer and whether or not 
chronic inflammation or hormones influence the cancer. 
1.6. Hypothesis and Objectives 
A previous study in Dr. Drover's laboratory reported that high levels of IFN-y 
transcripts in breast tumor tissues associated with increased survival in patients (Oldford 
et a!. , 2006), whereas high IL-6 levels and carriage of HLA-DR52 were associated with 
large tumors and decreased survival (Oldford, unpublished data). Since IL-6 is a 
proinflammatory cytokine that is required for the differentiation of nai"ve CD4+ T cells 
into proinflammatory T H 17 cells, we hypothesized an association between high 
intratumoral IL-6 and HLA-DR52 haplotypes with increased CD4+ T H 17 cells. We further 
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hypothesized that ifa TH17 profile significantly associated with IL-6 a nd HLA-DR5 2, it 
would a lso associa te with a poor prognosis and outcome. 
Stemming from this hypothesis, we developed the following objectives: 
Objectives: 
I. The first objective was to analyze a panel of breast cancer cell lines (BCCLs) for 
expression ofTH1 7 associated markers (IL-17 and RORc2) as well as IL-6 and TGF-
~ and FOXP3. FOXP3 and TGF-~ had previously been reported in established 
BCCLs (Karanikas et a!., 2008). If BCCLs expressed T H 17 associated transcripts, it 
would suggest the possibility that tumor cells in the breast cancer tissues also produce 
T H 17 associated transcripts, and raise serious concerns that a T H 17 profile based on 
IL-1 7 and RORc2 transcripts could produce false positive results. 
2. The second objective was to determine the levels of T H 17 associated transcripts (IL-
17 and R0Rc2) by real time RT-PCR and/or by immunohistochemistry in the breast 
cancer tissues and to use these values to derive a T H 17 profile. Since T H 17 cells are 
deri ved primarily from CD4+ T cells, we expected that a meaningful T Hl7 marker 
should be positively associated with increased numbers of infiltrating CD4+ T cells. 
3. The third objective was to statistically analyze whether a derived T H 17 profile or 
associated markers: i) correlated with levels of IL-6 transcripts; ii) associated with 
HLA-DR52 haplotypes; and iii) associated with poor prognosis, increased recurrence 
and decreased survival. With respect to prognostic indicators, I was to detennine if 
transcript level of IL- 17 and RORc2 corresponded to ERIPR status, HER2/neu status, 
tumor grade, lymph node positive patients and age at diagnoses. As these are 
41 
prognostic indicators, an association between T H 17 cell markers and these indicators 
may shed light on new potential therapies for breast cancer. 
42 
Chapter 2: Materials and Methods 
2.1. Breast Tumor Samples 
Breast cancer tissue samples were obtained from the Manitoba Breast Tumor 
Band (MBTB) (Winnipeg, Manitoba, Canada), with approval from the local Human 
Investigation Committee. Infonnation on tumor levels or ER and PR, age at diagnosis, 
clincopathological parameters and follow-up information were provided by the MBTB. 
In the initial study (Oldford et a!., 2006), frozen-tissue sections from 99 primary tumors 
were analyzed by IHC for tumor cell expression of HLA-DR, HLA-DM and Ii; T cell 
infiltrates (CD3, CD4 and CDS); B cell infiltrates (CD20) and infiltrating 
macrophages/dendritic cells (CD68). Eighty-nine tissues were fmi her analyzed by IHC 
for over expression of HER2/neu. Cytokine profiling (IFN-y, IL-1 ~. IL-2, IL-4, IL-6, IL-
l 0, TGF-~ and TNF-a transcripts) and FOXP3 transcripts were done on cloned DNA 
(eDNA) prepared from RNA extracted from frozen tissue sections and stored at -80°C. 
Detailed results of this study are available in Dr. Oldfo rd 's doctoral thesis (2006) and 
have been published in part (Oldford et a!, 2006). As part of the ongoing investigation 
fomarlin-fixed paraffin-embedded tissues from 40 patients were analyzed by IHC for 
dual-stained CD25+FOXP3+ Treg cells (Oldford, unpublished data). 
Sixty-five of the original RNA samples (from 65 patients), stored at -80°C, were 
available for this study, which focuses on T H 17 profi ling as described in Section 1.3.5. 
Table 2.1 A provides a numerical breakdown of the samples with respect to 
cl incopathologic factors, ER and PR status and age at diagnosis and leukocyte infiltrates. 
Table 2.1 B contains a comparison of the distribution of HLA haplotypes. Table 2. 1 C 
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provides a companson of the leukocyte cell surface markers. To ensure that the 65 
samples were representative of the initial 99 samples, we compared the distributio n of the 
relevant parameters in the original set to those in the subset of samples used in this study, 
the T H 17 subset (Table 2. 1 A, Table 2. 1 8 and Table 2.1 C). 
Table 2.1A. Comparison of the distribution of clinical and pathological features between 
the T H 17 subset and the original set. 
Prognostic Factor Original Set TH17 Subset P-valuea 
Count % Count % 
Tumor Size 
:S 2 em 24 25 14 25.9 NS 
> 2 em 72 75 40 74.1 
Tumor Type 
roc 80 83 .3 46 85.2 NS 
Others 16 16.7 8 14.8 
HistologicaL grade 
Grade IV - V 12 13.2 6 11.5 NS 
Grade VI - VII 44 48.4 27 5 1.9 
Grade VIII - IX 35 38.5 19 36.5 
CLinicaL Node Status 
Negative 45 45.9 23 42.6 NS 
Positive 53 54.1 3 1 57.4 
Estrogen Receptor0 
ER·ve 43 43.4 18 32.7 0.016* 
ER+ve 56 56.6 37 67.3 
Progesterone Receptor0 
PR·VC 34 34.3 15 27.3 NS 
PR+ve 65 65.7 40 72.7 
HER2/Neu 
Codes 0-2 70 78.7 39 81.3 NS 
Code 3 19 21.3 9 18.8 
Age of Diagnosis 
Mean 58.76 59.9& NS 
Median 60 62 NS 
*There was a s1gmficant difference between the ER status between the two cohorts. 
a. Pearson Chi Square 
b. Determined by ligand binding assays. Negative status was defined as ER or PR < 10 
fmollmg. Positive status was defined as ER or PR 2: 1 Ofmol/mg 
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Table 2.1 B. Comparison of the distribution of HLA haplotypes between the T H 17 subset 
and the original set 
Prognostic Factor Original Set T H17 Subset P-valuea 
Count % Count % 
DR52 
DR5Tve 50 50.5 25 45.5 NS 
DR52+ve 49 49.5 30 54.5 
DR52DQ2 
DR52DQTVC 84 84.8 46 83.6 NS 
DR52DQ2+ve:: 15 15 .2 9 16.4 
DR52DQ6 
DR52DQ6-vc 79 79.8 42 76.4 NS 
DR52DQ6+ve 20 20.2 13 23.6 
DR52DQ7 
DR52DQTve 77 77.8 42 76.4 NS 
DR52DQ7+ve 22 22.2 13 23 .6 
a. Pearson Chi Square 
Table 2.1 C. Comparison of the distribution of leukocyte infiltrates between the T H 17 
subset and the 01iginal set 
Prognostic Factor Origina l Set TH17 Subset P-valuea 
Count % Count % 
CD3 infiltrate 
None-Small* 41 41.4 23 41.8 NS 
Moderate-Large** 58 56.8 32 56.2 
CD4 infiltrate 
None-Small* 5 1 52.6 28 52.8 NS 
Moderate-Large** 46 47.4 25 47.2 
CD8 Infiltrate 
None-Small* 55 56.7 33 62.3 NS 
Moderate-Large** 42 43.3 20 37.7 
CD68 Infiltrate 
None-Smal l* 8 8. 1 3 5.5 NS 
Moderate- Large** 91 91.9 52 94.5 
a. Pearson Chi Square 
* Staining was positive for no or few scattered cells with small aggregate staining 
** Staining was positive for moderate to large number of cells with several small to 
large aggregate staining patterns 
The only significant difference between the two investigations was that the ER+ 
cases were increased in the T H 17 study in comparison to the original study. 
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2.2. Cell Lines 
Prior to analyzing the eDNA from breast tumor samples, a panel of BCCLs was 
analyzed by RT -PCR and real time-PCR for mRNA expression of IL-17, TGF-~, IL-6, 
RORc2, FOXP3, and glyceraldehyde-3-phosphatase dehydrogenase (GAPDH). Eight 
BCCLs, initially obtained from Ametican Type Culture Collection (A TCC), were 
analyzed by single nucleotide polymorphism (SNP) assays to ensure these lines were not 
contaminated by other cells (Allison Edgecombe's thesis, 2002). The cell lines were 
MDA-MB-435, T-47D, MDA-MB-231 , MCF-7, Hs 578T, MDA-MB-468, BT-474 and 
SK-BR-3 . The characteristics of the BCCLs are shown in Table 2.2 (Edgecombe, 2002). 
Table 2.2. Breast Cancer Cell Lines 
BCCL ATTC Morphology Description 
Identification* 
MDA-MB- HTB-129 Spindle- Ductal 
435 shape carcmcoma 
T-47D HTB-133 Epithelial Ductal 
carcmcoma 
MDA-MB HTB-26 Epithelial Adeno-
231 carcmoma 
MCF-7 HTB-22 Epithelial Adeno-
carcmoma 
SK-BR-3 HTB-30 Epithelial Adeno-
carcmoma 
Hs578T HTB-126 Epithelial Ductal 
carcmcoma 
MDA-MB- HTB-132 Epithelial Adeno-
468 carcmoma 
BT-474 HTB-20 Epithelial Ductal 
carcmcoma 
*Amen can Type Culture CollectiOn (A TCC) (Manassas, VA) 
**(Subik, eta!. , 20 I 0; Lacroix, eta!. 2004) 
ER PR 
status** status** 
- -
+ + 
- -
+ + 
-
-
- -
- -
+ + 
To determine the relative expression of transcripts by the BCCLs and the breast 
tumor samples, eDNA from control cells, known to express relevant cytokine transcripts, 
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were chosen. These inc! uded C I 0/MJ for IL-6, TCL-6D for FOXP3, J urkat for TG F -~ 
and human PBLs for IL-17 and R0Rc2. C l 0/MJ (Obtained from Dr. Michael Grant, 
original source: AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAID, NIH: ClO/MJ from Dr. Dean Mann and Dr. Miklaus Popovi), TCL-6D (provided 
by Dr. William Marshall) and Jurkat (original source: ATCC TIB-152) were available in 
the Drover lab. PBLs were isolated from whole blood using the Ficoll-Hypaque method 
(English and Andersen, 1974) and placed in RPMI 1640 media (Gibco) at a concentration 
of 2 x I 06 cells/mL. The PBLs were subsequently stimulated with phytohemagglutinin 
(PHA (MP Biomedical s, Soron, Ohio) at a concentration of 5 J.lg/ml and incubated for 12-
18 hours at 37°C in I 0% C0 2. Following the incubation period, the cells were collected, 
washed and RNA was extracted from the cells (Section 2.3.) 
2.3. RNA Extraction and Determination of RNA Integrity 
RNA was extracted from the BCCLs and the positive control cells using the Trizol 
reagent (Gibco BRL, Rockville, MD), followed by treatment with DNAse Free reagent 
(Ambion, Austin, TX) to remove contaminating DNA. 
RNA had previously been isolated from the breast tumor tissues by 
homogenization using Trizol reagent, followed by treatment with DNAse Free reagent 
and stored at -80°C. Prior to eDNA preparation and PCR analyses, RNA quality was 
analyzed using an Agilent 2 100 Bioanalyzer (Agilent Technologies, Ontario, Canada). If 
the RNA was too degraded, the results obtained from PCR analysis may not be an 
accurate representation of mRNA expression. Briefly, RNA integrity was tested using 
RNA Nano kits (Agilent Technologies, Ontario, Canada). The RNA sample undergoes 
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electrophoresis and an electropherogram is then constructed. A RNA integrity number 
(RIN) is assigned based upon an alg01ithm. If the RNA is intact, the RIN value can be as 
high as 10. Degraded RNA is considered to have RIN value less than 5. Based upon 
results presented by Fleige and Pfajjl (2006), we assigned the threshold of acceptable 
RIN values to be 5. They noted that variability among real-time PCR assays increased 
with RNA that was considered degraded (RIN = l-3) in comparison to RNA that was 
highly intact (RNA = 8-1 0) (Fieige and Pfaftl, 2006). Therefore, we assigned our cutoff 
to be 5. We found that 49 of the 65 available RNA samples had RIN values equal to or 
greater than 5. To avoid additional freezing and thawing of the RNA, eDNA was made 
for all 65 RNA samples at the same time as the samples were analyzed by the 
Bioanalyzer. 
eDNA was transcribed from the extracted RNA using the first strand eDNA 
synthesis kit (Fermentas, Thermo Fisher Scientific, Canada), according to the 
manufacturer's instructions. I 11g of RNA was transcribed into 20 ~-tL of eDNA, which 
provided the template for primers in RT-PCR and real-time PCR assays. 
2.4. Standard Reverse Transcriptase Polymerase Chain Reaction 
RT-PCR was done using a Biometra T Gradient thennocycler (Montreal Biotech 
Inc. , Quebec, Canada). Primers for IL-17 and GAPDH were purchased from Gibco 
(GIBCO, Invitrogen, Califomia, US) and primers for IL-6, TGF-P and FOXP3 were from 
Invitrogen (Carlsbad, Califomia, US). Sequences for the primers and expected base pair 
product size are listed in Table 2.3A. The IL-1 7 primer was designed using PrimerBlast 
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(National Center for Biotechnology Institute, Pubmed, US) and the National Center for 
Biotechnology Infonnation (NCBI) reference sequence numbers are given in Table 2.3B. 
Table 2.3A. Primer sequences for RT - PCR 
Gene Forward 5' to 3' Reverse 5' to 3' Predicted base 
pair size of 
amp! icon 
IL-17A GGA A TC TCC ACC GCA ACA CCA GT A TCT TCT 201 
ATGAG CCAGCC 
GAPDH TGA CCT TGC CCA CAG CAT CAC CAT CTT CCA 443 
CCTTG GOA GCG 
IL-6 AGC TCA GCT A TG AAC GTC TCC TCA TTG AA T 338 
TCCTTCTC CCAGATTGG 
FOXP3 CAG CTG CCC ACA CTG CAT TTG CCA GCA GTG 382 
CCC CTA G GGTAG 
TGF-~ GCC CTG GAC ACC AAC AGG CTC CAA A TG TAG 
TATTGC GGGCAGGG 160 
Table 2.38. NCBI Reference Sequences for RT - PCR primers 
Primer Reference Sequence 
IL-17 A NM 002190.2 
GAPDH NM 001256799.1 
IL-6 NM 000600.3 
FOXP3 NM 014009.3 
TGF-~ NM 000660.4 
All PCR reactions were performed in a volume of 50 11L with 200mM of dNTPs 
(Invitrogen, California) and 1 ~tL of eDNA. Samples containing ultrapure distilled water 
(molecular water) (GIBCO) instead of eDNA were included as contamination controls. 
eDNA from cell lines C 10/MJ, Jurkat, TCL-6D and PBLs, from a healthy donor (HLA 
04), stimulated with PHA, were used as positive controls as described in Section 2.2. 
GAPDH was used as the endogenous housekeeping control. Primers were used at 
concentrations of 20 pM for IL-17 and GAPDH and I 0 pM for IL-6 and TGF-~ . The 
optimal primer concentration was determined by running parallel reaction mixtures using 
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different concentration of primers. lf the primer concentration was too high, pnmer 
dimers and non-specific binding could occur. Altematively, if the primer concentration 
was too low, insufficient specific template binding could occur, thereby lowering the PCR 
product. The optimal concentration of MgC12 (Invitrogen) was determined to be 2.0 mM 
for all reactions; 0.2 )!L ofTaq DNA polymerase (Invitrogen) was used for all reactions. 
All reaction mixtures were denatured at 94°C for 1 minute. The optimal annealing 
temperature was determined using a temperature gradient. As noted previously, the 
melting points of the primers were determined using the program Primer BLAST 
(Pubmed) and a temperature gradient was chosen based upon the melting temperature. 
Optimal annealing temperature is notmally within 5°C of the melting temperature of the 
primer (PCR Amplification, 2012). The denaturation and extension steps remained the 
same during the gradient and the number of cycles was consistent at 35. The extension 
step of the PCR was 72°C for 1 minute for all the primers, except for GAPDH (3 
minutes). The optimal cycle number for each primer set was also determined to avoid 
over or under amplification of the desired transcript. Section 3.2. provides the results of 
determining the annealing temperature and cycle number. 
Following the amplification cycling, PCR products were loaded on three 1.5% 
agarose gel (prepared with agarose dissolved in 45 mM Tris-borate I mM EDTA (TBE) 
containing ethidium bromide (2 )!L) and visualized using UV light in a Kodak Imager. 
The base pair size of the PCR product was estimated by comparison to a 100 base pair 
ladder (Fennentis, Thermo Fischer Scientific, Canada). Using Kodak Molecular Imaging 
Software V.4.0.0. (Kodak, St. Rochester, New York), the density of the bands were 
determined and the intensity of the bands was expressed as a relative quantity using the 
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following formula: ((target gene in sample)/(GAPDH m sample)) ((target gene m 
positive control)/(GAPDH in positive control)). 
2.5. Real Time Polymerase Chain Reaction 
Real time PCR was perfonned using a StepOne Real Time PCR System and 
Software (Applied Biosystems, Life Technologies, Carlsbad, Califomia). 
IL-17, RORc2, and GAPDH transcripts were analyzed in the 65 breast tumor 
samples (from 65 patients). TaqMAN® Gene Expression Assays for GAPDH 
(Hs99999905_ml) and lL-17 (HS00174383_ml) were available from Applied 
Biosystems whereas the RORc2 assay was custom designed (Olivito et a!., 2009). The 
sequences of RORc2 specific primers are given in Table 2.4. 
Table 2.4: Real time PCR RORc2 primer sequences 
Target transcript Forward Primer Reverse Primer Probe (FAM) 
R0Rc2 5'-GAA GOA CAG 5'- CTT GTC CCC 5' - TCA GTC 
GOA GCC AAG ACA GAT TIT ATG AGA ACA 
GC-3' GCA-3' CAA ATI GAA 
GTG ATC CC -3 ' 
For all assays, the reporter dye was FAM™, a fluorescent dye, at the 5' end of the 
TaqMAN® minor groove binder (MOB) probe. A nonfluroescent quencher was at the 3 ' 
end of the probe. The TaqMAN® MOB probes and primers were premixed in a 20X 
solution. The concentration of the primers and probes were I 8 J..LM and 5 J..LM, 
respectively. TaqMAN Gene Expression Master mix (Applied Biosystems) was for PCR 
applification. The premade master mix contains Amplitaq® Gold DNA Polymerase 
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Ultra-Pure, Uracil DNA glycosylase, dNTPs, ROX™ Passive Reference and buffer 
components. 
The PCR mixtures were 20 ~tL in total. There was 10 ~L of TaqMan Gene 
Expression Master Mix, 1 ~tL of specific primer/probe, 1 ~L of eDNA and 8 ~L of 
molecular water. The optimal concentration of eDNA added to each reaction was 
determined through serial dilution assays described in Section 3.5. The condi tions of the 
thennal cooling and heating cycles were unifotm for all 4 transcripts analyzed and are 
given in Table 2.5. 
Table 2.5: Real time PCR amplification conditions 
Amplification Time 
Step l: 50°C 2 minutes 
Step 2: 95°C 10 minutes 
Step 3: 95°C 15 seconds 
60°C l minute repeat for 40 cycles 
Each sample was tested in triplicate to ensure accuracy and real-time analysis of 
lL-1 7 was done on two separate occasions. The data were analyzed using the formula 2-
MCt and expressed as a fo ld-increase. The C1 is the relative measure of the concentration 
of a target in the PCR reaction. The C, is also inversely proportional to the amount of 
target nucleic acid in the sample. The relative quantity of the target gene is expressed in 
tetms of comparative relative quantity. The two separate genes, such as RORc2 or IL- 17 
and the endogenous control, GAPDH, were amplified in separate tubes. The C, for each 
sample was detenn ined by the StepOne program and the C1 for the endogenous control 
was subtracted from the C, of the gene of interest (~C,) . Each ~C1 was subtracted from 
the ~C1 that was the largest (~~C1). This number is then used as an exponent of 2. 
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Therefore, the fonnula used to calculate the relative quantity is 2-MCt. The average and 
standard deviation was calculated. 
2.6. Immunohistochemistry 
The prior Sections 2.3 - 2.5 described methods to determine transcript levels in 
the RNA extracted from bulk tumors obtained from the MBTB. To confirm and validate 
results obtained by PCR, we planned to assess relevant protein expression using IHC. 
Sections from 40 tumor blocks (from 40 unique patients), that had been fonnalin-fixed 
and paraffin-embedded (FFPE), were obtained from MBTB and we planned to test these 
tumors blocks by IHC forTH 17 associated markers. 
Dual staining methods had been previously catTied out to identify CD25+FOXP3+ 
T cells on a set of the sections from the same FFPE tissue blocks. The cytoplasm was 
stained with CD25 antibody (Vector, Burlingame, CA) and the nucleus was stained using 
FOXP3 antibody (Abeam, Cambridge, MA). A similar procedure was conducted for this 
work, using antibodies for RORc (Imagnex, San Diego, CA) and FOXP3 to stain the 
nucleus and antibodies for IL-17 (Santa Cruz, Santa Cruz, CA) or CD3 (Abeam) to stain 
the cytoplasm. Two antibodies for RORc were optimized (Imagnex, IMG60 13A and 
IMG71896). FOXP3 and CD3 were the nuclear and cytoplasmic positive controls. 
Additionally, HER2 (Dako, Agilent Technologies) antibody (2 ).lg/mL) was used as a 
control to ensure that the secondary antibody, anti-rabbit, was working properly. This 
antibody had been optimized in our laboratory previously (Drover, unpublished data). 
Mouse and Rabbit immunoglobulins (Vector) were used for the negative controls using 
dilutions that matched the primary antibody used. However, there were problems 
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encountered in the optimization phase and dual staining of the FFPE tissue blocks did not 
occur. Section 3.8. describes the optimization results. 
2.6.1. Preparation of IHC slides 
Prior to staining the FFPE sections, antigen retrieval and staining conditions were 
optimized. Positive control tissues for RORc and IL-17 were thymus and tonsil slides, 
respectively. Paraffin was removed by soaking the slides in xylene for 10 minutes twice. 
This was followed by rehydration in I 00% ethanol for 30 seconds 3 times, then 95% 
ethanol for 30 seconds twice and 70% ethanol once. The slides were then placed 111 
deionized water for 5 minutes and the water was circulated using a magnetic stir bar. 
2.6.2. Antigen Retrieval 
The next step involved antigen retrieval which is necessary because during the 
fixation process, antigenic epitopes are frequently lost due to cross-linking of proteins by 
fonnalin. Sodium citrate buffer, O.OIM solution, was made by dissolving 0.588 grams of 
sodium citrate (Fisher Scientific Company, New Jersey, USA) in 200 mL of deionized 
water. The pH of the solution was adjusted to 6 using concentrated hydrochloric acid 
(Fisher Scientific Company). During antigen retrieval, the slides being prepared for CD3, 
[L-1 7 and RORc staining were placed in a canister containing the sodium citrate buffer 
and steamed in a hot water bath at I 00°C. The time required for antigen retrieval of the 
CD3, IL-1 7 and RORc epitopes was 20 minutes, 60 minutes and 60 minutes, respectively. 
Slides being prepared for FOXP3 staining were placed in a canister containing cell 
conditioning buffer, CCl (Vector) (pH=8) and steamed in a hot water bath at I 00 oc for 
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60 minutes. The slides were then left to cool for 20 minutes and followed by washing 
using a 1% phosphate buffered saline (PBS) solution and Tween (Fisher Scientific 
Company) solution. Each PBS/Tween washing step consisted of three five minute 
washes in PBS/Tween. 
2.6.3. Antibody Staining 
Prior to addition of the primary antibody, non-specific binding was prevented by 
applying two drops of Normal Horse Serum (NHS) (Vector Labs) to the slides for 30 
minutes in a humidified environment at room temperature. Following removal of the 
NHS, the primary antibody was optimally diluted in Ventana Antibody Diluent (VAD) 
Buffer (Ventana, Tucson, AZ). An optimal concentration range for each antibody was 
provided from the company to determine the concentration which gave the best signal to 
background staining. Optimal concentrations of the primary antibodies and conditions 
are given in Table 2.6. 
Table 2.6: Primary antibody application conditions 
Antibody Concentration Time period Temperature 
RORc (IMG6013A) 15 11g/mL 45 minutes Room temperature 
RORc (IMG7 1896) 20 ~Lg/mL 60 minutes Room temperature 
FOXP3 5 ~Lg/mL 120 minutes Room temperature 
IL-17 0.5 ~Lg/mL Overnight 4 °C 
CD3 6/ 100 ~LL 60 minutes Room temperature 
The primary antibody was removed from the slides using three O.lM PBS I 0.1 % 
Tween washes. Next, 100 IlL of 0.3% hydrogen peroxide was applied to the slides for 10 
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minutes at room temperature, followed by three PBS/Tween washes. The H202 blocks 
endogenous peroxidases within the section to prevent false staining. 
The secondary antibody was then added using two drops of anti-mouse (Vector) 
and anti-rabbit (Vector) for CD3/FOXP3 and IL-17/RORc, respectively. After the 30 
minute incubation the antibodies were removed followed by washing three times in 
PBS/Tween. Vector diaminobenzidine (DAB) or Vector SG Blue were used as the 
substrate and incubation times varied between 5 - 15 minutes at room temperature, 
followed by a wash in deionized water. 
Dual staining of slides follows the same procedure of antigen retrieval, blocking, 
addition of the second primary antibody followed by secondary antibody application and 
staining. Generally for dual staining, SG blue was used for cytoplasmic staining and 
DAB was used for nuclear staining. 
2.6.4. Dehydration and Mounting 
After washing the sections were next dehydrated and mounted which consisted of 
soaking in 70% ethanol for 1 minute, 2 changes of 95% ethanol for 1 minute, 3 changes 
of l 00% ethanol for 1 minute and 2 changes of xylene for 2 minutes. The slides were 
then mounted, dried and examined using light microscopy. 
2.6.5. Breast tumor sample IHC 
Although resources were used to optimize the conditions for the IL-1 7 and RORc 
lHC antibodies, a high degree of uncertainty remained due to granular staining pattems 
and high background for both antibodies. We had confidence in our methods as the dual 
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staining was successful for CD3 and FOXP3. Furthennore, both RORc antibodies were 
not specific for RORc2 and an antibody designed for just RORc2 did not exist. Therefore, 
subsequent experimentation on the 40 breast tumors was not carried out. Section 3.8. 
provides the results of the experiments conducted. 
2. 7. Statistical Analysis 
Analysis was perfonned usmg SPSS Version 19 Stati stical Software. 
Contingency tables were analyzed using Person's chi-square. Non-parametric Mann 
Whitney U or Kruskal-Wallis H test were used to assess statistical significance of 
continuous variables, with the exception of age at diagnosis, which was notmally 
distributed and assessed by one way analysis of variance (ANOV A). 
Survival estimates were calculated using Kaplan-Meier method with log-rank 
statistic. Ninety-five percent confidence intervals (95% CI) around each estimate were 
calculated using the standard error (SE) of cumulative survival probability (95% CI = 
cumulative survival probability± 1.96 x SE). Estimates were calculated as time to distant 
metastasis for distant RFS. No patients were lost to follow up and patients without 
recurrence were censored at the time of last follow up or at 5 years for 5-year survival. 
For survival analysis, normalized cytokine and transcript factor units were stratified into 
high and low categories (the high category refers to values that were greater than the 
median of the data collected). 
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Chapter 3: Results 
3.1. Optimization of RT-PCR Conditions 
Optimal conditions for the RT-PCR amplification with primers used in this study 
were detennined. The following subsections of Section 3. 1. describe the optimization 
procedures and results. 
3.1.1. Optimal RT-PCR Annealing Temperatures 
The primers are described in Section 2.4. For each primer, an initial RT-PCR 
experiment was conducted to detennine the optimal annealing temperature. The annealing 
temperature gradient was chosen based on the melting temperatures of the primers. 
Generally, temperatures ± soc of the melting temperature of the primer were included in 
the temperature gradient. The conditions for denaturation and extension remained 
constant for the annealing temperature gradient experiments, i.e. 94°C for 1 minute for 
denaturation and 72 oc for 1 minute for extension. Figure 3. 1. shows a representative gel 
of the annealing temperature gradient for the IL- 17 primer set. The PCR products were 
loaded in a 1.5% agarose gel, viewed under UV light and digitized (see Section 2.4 for a 
more in depth description). 6 l.6°C was chosen as the optimal annealing temperature for 
IL- 17 primers based on a comparison of the density of the amplicon bands. 
The optimal annealing temperatures fo r the other primers used in this study were 
detenn ined using the same method. Table 3. 1. shows a list of the primers and the 
associated annealing temperature. 
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Table 3.1. Annealing temperatures and times of RT-PCR Primers 
Primer Annealing Temperature (°C) Atmealing time 
IL-17 6 1.6 60 seconds 
IL-6 64 60 seconds 
TGF-B 65 60 seconds 
FOXP3 65 60 seconds 
The denaturation and extension temperatures for all pti mers were 94°C and 72°C, 
respectively. T he time required for denaturation was 60 seconds fo r all the primers. The 
extension step was 60 seconds for all the primers, except for GAPDH (180 seconds, 
previously determined in the Drover laboratory). 
3.1.2. Optimal RT-PCR Amplification Cycle Number 
If transcripts were under-amplified, the target transcript would appear to be 
present 111 lower amounts, leading to fa lse negatives. Conversely, over-amplification 
would result in eDNA samples appearing to have higher amounts of target transcript and 
lead to positive results that could not be quantified. We, therefore, performed preliminary 
experiments to determine the optimal RT -PCR amplification number for each primer pair. 
3.1.2.1. Determination of Optimal RT -PCR Amplification Cycle for IL-17 
The transcript lL-17 was amplified over even cycles between 22-38. Figure 3.2A 
shows a representative gel of the amplification of the IL-1 7 transcript over the cycle 
range. The bands, from three separate gels, were digitized and the mean band density is 
plotted in Figure 3.2B. The results of the PCR assay were as expected with amplification 
occutTing over an exponential phase followed by a linear (plateau) phase (Figure 3.2B). 
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Figure 3.1. Determination of the optimal annealing temperature for /L-1 7. Based on 
the software program, PRIMER-Blast, the melting temperatures, Tm, ofthe forward IL-17 
primer was 53 .93 oc and the melting temperature of the reverse IL-l 7 primer was 
53 .38°C. A temperature gradient was constructed using annealing temperatures 56°C 
(lane 2), 58°C (lane 3), 60.4°C (lane 4), 61 .6°C (lane 5), 64°C (lane 6) and 66°C (lane 7). 
Lane 1 contained the 100 base pair ladder. The negative control (NC) is in the last lane. 
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B) 
IL-17 Optimization 
26 28 30 32 34 36 38 
Cycle Number 
Figure 3.2. Determination of the optimal PCR amplification cycle for IL-1 7 transcripts. 
A) Representative image showing products for cycle 22 (lane 2), 24 (lane 3), 26 (lane 4), 
28 (lane 5), 30 (lane 6), 32 (lane 7), 34 (lane 8), 36 (lane 9) and 38 (lane 10). Lane 1 
contained the 1 00 base pair ladder. The last lane has the no template control. B) PCR 
products were run in three replicate gels, digitized using Kodak Molecular Imaging, and 
the mean and error bars (representing 1 standard deviation of the mean of the three 
replicate gels) were graphed. 
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Analyzing the exponential phase, three cycles were chosen for the subsequent log 
fold dilution assay; cycles 30, 32, and 34. The PCR products of the log fold dilution are 
shown in Figure 3.3A and the digitized values were plotted in Figure 3.3B. Theoretically, 
at the optimal cycle number, the log-fold diluted PCR products should yield a straight line 
when plotted. Using Figure 3.3B, cycle 32 was chosen as the optimal cycle number for 
amplification of IL-1 7 as this produced the most linear line as determined by slope. 
3.1.2.2. Determination of Optimal RT -PCR Amplification Cycle for IL-6 
The transcript IL-6 was amplified over the even cycles between 24-38. The PCR 
products (Figure 3.4A) were digitized and the average number of pixels was graphed 
(Figure 3.4B), illustrating the amplification over increasing cycle numbers. The results 
were as expected, showing an exponential phase, followed by the plateau. 
Cycles 34 and 35 were chosen from the exponential phase (Figure 3.4B) for the 
serial dilution assay (Figure 3.5A-B). Following analysis of the graphs in Figure 3.5B, 
cycle 35 log fold dilution was the most linear and therefore, cycle 35 was chosen as 
optimal cycle number for amplification of IL-6 transcripts. 
3.1.2.3. Determination of Optimal RT-PCR Amplification Cycle for TGF-~ 
The transcript TGF-P was amplified over the even cycles between 18-40. The 
PCR products (Figure 3.6A) were digitized and the average number of pixels was graphed 
(Figure 3.68), illustrating the amplification over increasing cycle numbers. The results 
were as expected, showing an exponential phase, followed by the plateau. 
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Figure 3.3. IL-1 7 amplification of log-fold diluted eDNA. A) Representative image 
showing the PCR products during cycle 30 (lanes 2-4), 32 (lanes 5-7) and 34 (lanes 8-1 0). 
Lanes 2, 5 and 8 were PCR mixtures with 1 JlL of eDNA, lanes 3, 6 and 9 contained a 1 
fold log dilution of eDNA and lanes 4,7 and 10 contained 2 fold log dilution of eDNA. 
Lane 1 contained the 100 base pair ladder. The last lane has the no template control. B) 
PCR products were run in three replicate gels, digitized using Kodak Molecular Imaging, 
and the mean and error bars (representing 1 standard deviation of the mean) were 
graphed. 
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Figure 3.4. Determination of the optimal PCR amplification cycle for /L-6 transcripts A) 
Representative image showing products for cycle 24 (lane 2), 26 (lane 3), 28 (lane 4), 30 
(lane 5), 32 (lane 6), 34 (lane 7), 36 (lane 8) and 38 (lane 9). Lane 1 contained the 100 
base pair ladder. The last lane has the no template control (NC). B) PCR products were 
run in three replicate gels, digitized using Kodak Molecular Imaging, and the mean and 
error bars (representing 1 standard deviation of the mean) were graphed. 
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Figure 3.5. IL-6 amplification of log-fold diluted eDNA. A) Representative image 
showing the PCR products during cycle 34 (lanes 2-4) and 35 (lanes 5-7). Lanes 2 and 5 
PCR mixtures with 1 jlL of eDNA, lanes 3 and 6 contained a 1 fold log dilution of eDNA 
and lanes 4 and 7 contained a 2 fold log dilution of eDNA Lane 1 contained the 100 
base pair ladder. The last lane has the no template control (NC). B) PCR products were 
run in three replicate gels, digitized using Kodak Molecular Imaging, and the mean and 
error bars (representing 1 standard deviation of the mean) were graphed. 
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Figure 3.6. Determination of the optimal PCR amplification cycle for TGF-fJ transcripts 
A) Representative image showing products for cycle 18 (lane 2), 20 (lane 3)22 (lane 4), 
24 (lane 5), 26 (lane 6), 28 (lane 7), 30 (lane 8), 32 (lane 9), 34 (lane 10), 36 (lane 11), 38 
(lane 12) and 40 (lane 13). Lane 1 contained the 100 base pair ladder. The last lane has 
the no template control (NC). B) PCR products were run in three replicate gels, digitized 
using Kodak Molecular Imaging, and the mean and error bars (representing 1 standard 
deviation of the mean) were graphed. 
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Cycles 31 and 32 were chosen from the exponential phase of Figure 3. 7B for the 
seri al dilution assay (Figure 3.7 A-B). Following analysis of the graphs in Figure 3.7B, 
cycle 3 1 log fold dilution was linear and therefore, cycle 31 was chosen to be the optimal 
cycle number for TGF-P amplification. 
3.1.2.4. Determination of Optimal RT -PCR Amplification Cycle for FOXP3 
The transcript FOXP3 was amplified over the even cycles between 28-42. The 
PCR products (Figure 3.8A) were digitized and the average number of pixels was graphed 
(Figure 3.8B), illustrating the amplification over increasing cycle numbers. The results 
were as expected, showing an exponential phase, followed by the plateau. 
Cycles 33 , 34 and 35 were chosen from the exponential phase of Figure 3.8B for 
the serial dilution assay (Figure 3.9A-B). Following analysis of the graphs in Figure 
3.8B, cycle 33 log fold dilution was linear and therefore, cycle 33 was chosen to be the 
optimal cycle number for FOXP3 amplification. 
3.1.2.5. Summary ofRT-PCR Cycle Number Optimization 
RT -PCR optimization was successfully completed for lL-1 7, IL-6, TGF-P and 
FOXP3. The optimal cycle numbers are listed in Table 3.2. Similar attempts were made 
to optimize two different RORc2 primer sets. However, despite considerable efforts, we 
were not successful. Following reconstitution of both primer sets, the specific band 
would fade gradually and primer dimers became the dominant product. Therefore, we 
decided to test RORc2 by real-time PCR only. 
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Figure 3.7. TGF-fJ amplification of log-fold diluted eDNA. A) Representative image 
showing the PCR products of cycle 31 (lanes 5-7) and 32 (lanes 2-4). Lanes 2 and 5 PCR 
mixtures with 1 J..lL of eDNA, lanes 3 and 6 contained a 1 fold log dilution of eDNA and 
lanes 4 and 7 contained a 2 fold log dilution of eDNA. Lane 1 contained the 100 base 
pair ladder. The last lane has the no template control (NC). B) PCR products were run in 
three replicate gels, digitized using Kodak Molecular Imaging, and the mean and error 
bars (representing 1 standard deviation of the mean) were graphed. 
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Figure 3.8. Determination of the optimal PCR amplification cycle for FOXP 3 transcripts 
A) Representative image showing products for cycle 28 (lane 2), 30 (lane 3), 32 (lane 4), 
34 (lane 5), 36 (lane 6), 38 (lane 7), 40 (lane 8) and 42 (lane 9). Lane 1 contained the 100 
base pair ladder. The last lane has the no template control (NC). B) PCR products were 
run in three replicate gels, digitized using Kodak Molecular Imaging, and the mean and 
error bars (representing 1 standard deviation of the mean) were graphed. 
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Figure 3.9. FOXP 3 amplification of log-fold diluted eDNA A) Representative image 
showing the PCR products of cycle 33 (lanes 2-4), 34 (lane 5-7) and 35 (lanes 8-10). 
Lanes 2, 5 and 8 PCR mixtures with 1 ~of eDNA, lanes 3, 6 and 9 contained a 1 fold 
log dilution of eDNA and lanes 4, 7 and 10 contained a 2 fold log dilution of eDNA. 
Lane 1 contained the 100 base pair ladder. The last lane has the no template control 
(NC). B) PCR products were run in three replicate gels, digitized using Kodak Molecular 
Imaging, and the mean and error bars (representing 1 standard deviation of the mean) 
were graphed. 
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Table 3.2. Optimal cycle numbers 
IL-17 IL-6 TGF-P FOXP3 
Cycle Number 32 34 31 33 
3.2. RT -PCR Analysis of Cytokine and Transcription Factors Transcripts in Breast 
Cancer Cell Lines 
A recent study reported FOXP3 transcripts 111 several human cancer cell lines, 
including BCCLs (Karanikas et al. , 2008). Therefore, our first objective was to 
investigate if BCC Ls had IL-17 and other cytokine transcripts found within a tumor 
environment. To test this, a panel of eight BCCLs (as described in Section 2.2.) was 
analyzed by RT-PCR to detennine if IL-1 7, IL-6, TGF-P and FOX P3 transcripts were 
present. As shown in Figure 3.1 0, no IL-1 7 was detected in any of the eight BCCL 
suggesting that if transcripts were detected in the eDNA from breast cancer tissues, T 
cells, or other infiltrating cells, such as macrophages, would produce them. IL-6 was 
present in higher levels in Hs 578 and MDA-MB-23 1 (Figure 3.11 A-B). By contrast, all 
cell lines except T-470 , SK-BR-3, BT-474 expressed large amounts ofTGF-P transcripts 
(Figure 3. 12A-B), indicating that this marker is not a useful marker for profiling 
regulatory T cell s. FOXP3 was present in all BCCLs in low amounts, which contradicts 
findings by Karanikas eta!. (2008) (Figure 3. 13A-B). Therefore, it is unclear whether 
high levels ofFOXP3 transcripts detected in breast tumor tissue are produced from only T 
cells. 
Based on the above results and the literature provided in Chapter 1, we decided to 
analyze both IL-17 and RORc2 by real-time PCR as these are related toT H 17 cells. 
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Figure 3.11. BCCL expression of IL-6. A) Representative image of relative levels ofiL-6 
in BCCLs. The cell line represented by the PCR product is shown beneath the band; 
C 1 0/MJ, the positive control; NC, no template control (NC). B) PCR products were run in 
three replicate gels, digitized using Kodak Molecular Imaging, and the mean and standard 
deviation were calculated and graphed. The relative expression is defined as ((IL-6 in 
BCCL)/(GAPDH in BCCL)) 7 ((IL-6 in CIO/MJ)/(GAPDH in CIO/MJ)). 
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Figure 3.12. BCCL expression of TGF-fJ. A) Representative image of relative levels of 
TGF-P in BCCLs. The cell line represented by the PCR product is shown beneath the 
band; Jurkat the positive control; NC, no template control (NC). B) PCR products were 
run in three replicate gels, digitized using Kodak Molecular Imaging, and the mean and 
standard deviation were calculated and graphed. The relative expression is defined as 
((TGF-p in BCCL)/(GAPDH in BCCL)) 7 ((TGF-p in Jurkat)/(GAPDH in Jurkat) 
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Figure 3.13. BCCL expression of FOXP3. A) Representative image of relative levels of 
FOXP3 in BCCLs. The cell line represented by the PCR product is found beneath the 
band; TCL6D, the positive control; NC, no template control (NC). B) PCR products were 
run in three replicate gels, digitized using Kodak Molecular Imaging, and the mean and 
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We analyzed both transcripts as both IL-17 and RORc2 are not exclusively produced by 
T H 17 cells. 
3.3. RNA Integrity Values for Breast Tumor RNA 
When eDNA was prepared from the 65 breast tumor RNA samples, the RNA 
integrity was also tested. The RNA samples were stored for 6 years at -80°C and there 
were some concerns over RNA degradation. If RNA is greatly degraded, the analysis and 
interpretation of PCR results may be inaccurate. The RIN algorithm is extracted from 
electrophoretic measurements from the Agilent BioAnalyzer. The value obtained ranges 
between I (worst RNA quality) and 10 (best RNA quality). The RNA RIN values are 
shown in Table 3.4. 
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Table 3.4. RlN Values for Breast Cancer RNA Samples 
Sample RIN Sample RIN Sample RfN 
11378 2.2 11129 5.9 11216 7.5 
12159 2.7 11644 6 11170 7.5 
11372 2.7 12418 6.2 11799 7.6 
13088 2.9 12078 6.3 13451 7.7 
11353 2.9 11882 6.4 11499 7.7 
13058 3.3 11 815 6.4 1088 1 7.8 
13167 3.5 10850 6.4 11565 7.9 
1311 3 3.7 12375 6.6 13369 8 
11 208 3.7 10958 6.6 11 905 8 
11084 3.8 12858 6.8 11817 8.1 
11 889 4.3 12816 6.9 11108 8. 1 
11452 4.3 11657 6.9 13412 8.2 
12748 4.4 12750 7.1 13269 8.2 
I 1816 4.5 11 818 7.1 131 23 8.2 
13390 4.8 11008 7.1 13337 8.4 
11066 5.2 111 25 7.2 10832 8.6 
1283 1 5.3 12450 7.3 11556 8.8 
12513 5.3 10796 7.3 14377 8.9 
11432 5.3 12782 7.4 12694 9.1 
11 894 5.7 11 352 7.4 12483 9.1 
11 834 5.8 13282 7.5 125 11 NA 
12926 5.9 11 806 7.5 
RIN values ranged from 2.2 - 9.1 , with a median of 6.85 and a mean of 6.34. 
Sixteen of the samples had RfN values less than 5. However, as the eDNA was already 
prepared, RT-PCR and real-time experiments were conducted on all 65 samples, with the 
exception of the second testing of IL-1 7 by real-time PCR. 
3.4. Analysis of Cytoldne Transcdpts in Breast Cancer Tissues by Conventional RT-
PCR 
IL-6 transcript levels were detennined by RT-PCR for the 65 breast tumor 
samples. Table 3.5. and Figure 3. 14A. provide the results obtained for both the 65 
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samples (all RfN values) and 49 samples (RIN 2: 5). Figure 3. 14A shows that the data are 
not nonnally distributed for all 65 samples. Figure 3.148 shows that exclusion of the RIN 
values less than 5 does not change the result that the data are not normally distributed. 
Therefore, for statistical analysis, nonparametric statistical tests were used. 
Table 3.5. Descriptive statistics of RT-PCR transcript levels of IL-6 
IL-6 (N=65) IL-6 (N=49) 
Mean 178.9 164.7 
Median 149.1 149.5 
Range 699.9 699.9 
The IL-6 values obtained on the 65 samples were compared to the first set of IL-6 
values on the same samples in the initial study, using Spearman's correlation test, 
p=0.114 (N=64) or p=0.049 (N=48). There is a significant coiTelation between the two 
sets of data obtained when samples with RIN values greater or equal to 5 were used, 
demonstrating that the results are reproducible. 
Relative lL- 17 transcript levels were also detennined for the 65 breast tumor 
eDNA samples. These results are summarized in Table 3.6. and Figure 3. 15A-B. Once 
again, the data are not normally distributed; therefore nonparametric statistical tests were 
used for analysis. 
Table 3.6. Descriptive statistics of RT-PCR transcript levels of IL-1 7 
IL-1 7 (N=65) lL- 17 (N=49) 
Mean 14.22 11.93 
Median 8.5 7.8 
Range 71.9 7 1.9 
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Figure 3.14A. IL-6 transcript expression in BCT samples. The figure shows the 
distribution ofiL-6 transcript levels analyzed by conventional RT -PCR in 65 breast tumor 
samples. The data are not normally distributed. 
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Figure 3.14B. IL-6 transcript expression in BCT samples. The figure shows the 
distribution of ll.,-6 transcript levels analyzed by real-time PCR in 49 breast tumor 
samples. The data are not normally distributed. 
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These values reflect the mRNA levels of IL-17 obtained through conventional 
RT-PCR experiments and are compared later to the values obtained by real-time PCR in 
Section 3.7. Table 3.7. summarizes the correlations obtained between IL-17 and IL-6. 
The IL-6 transcript levels from both subsets associate significantly (RIN 2:5). As a result, 
we had confidence that the level of IL-6 detected by our RT-PCR experiments was 
accurate. 
Table 3.7. Speatman's rho significance for RT-PCR relative transcripts ofiL-6 and IL-17 
(N=49) 
IL-6 (original set) IL-6 lL-17 
RIN<5 I RIN2:5 RIN<5 I RIN2:5 RIN<5 I RIN2:5 
IL-6 (original set) 
IL-6 (T H 17 subset) 0.114 0.049* 
IL-17 NS NS NS NS 
3.5. Optimization of Real-time PCR Conditions 
Real-time PCR kits were obtained from Invitrogen, as previously described in 
Section 2.5. The denaturation, annealing and extension steps were predetermined for 
these real-time PCR kits, but the quantity of eDNA required optimization. Section 2.3. 
describes the process involved in converting 1 11g of RNA into 20 IlL of eDNA. Five log 
fold dilutions (I ~tL - Ill 0000 IlL)) of the positive control eDNA were prepared for 
amplification, which was preformed over 40 cycles (see Section 2.5. for the conditions). 
Figure 3. 16A-B contain the amplification plots obtained for IL-1 7 and RORc2 transcripts 
in HLA-04, the positive control. An optimal threshold for detection of fluorescence from 
the F AM TM is selected automatically from regression parameters of the standard curve. 
A threshold cycle (Ct) for each volume is assigned based upon the intersection of the 
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Figure 3.15A. IL-1 7 transcript expression in BCT samples. The figure shows the 
distribution of a-17 transcript levels analyzed by conventional RT -PCR in 65 breast 
tumor samples. The data is not normally distributed. 
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Figure 3.15B. IL-1 7 transcript expression in BCT samples. The figure shows the 
distribution of ll.,-17 transcript levels analyzed by real-time PCR in 49 breast tumor 
samples. The data is not normally distributed. 
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Figure 3.16A. Determining the optimal dilution of eDNA for real-time assays A) IL-17 
amipli.fication. Log fold dilutions of HLA04 were amplified in the StepOne Real-Time 
PCR machine over 40 cycles. The red line represents amplification of 1 ~of eDNA, the 
yellow lines represents amplification of a 1 fold log dilution of eDNA, the light green line 
represents amplification of a 2 fold log dilution of eDNA and the dark green lines 
represents amplification of a 3 fold log diltuion of eDNA~ of eDNA and the blue line 
represents amplification of a 5 fold log dilution of eDNA The number of amplifications 
is represented by the x-axis and ARn is represented by the y-axis. ARn is the fluorescence 
ofthe reporter dye (FAM) divided by the fluorescence ofthe passive dye (ROX). Assays 
were performed in duplicate. 
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Figure 3.16B. Determining the optimal dilution of eDNA for real-time assays B) RORc2 
amplification. Log fold dilutions of HLA04 were amplified in the StepOne Real-Time 
PCR machine over 40 cycles. The red line represents amplification of 1 ~of eDNA, the 
yellow lines represents amplification of a 1 fold log dilution of eDNA, the light green line 
represents amplification of a 2 fold log dilution of eDNA and the dark green lines 
represents amplification of a 3 fo ld log diltuion of eDNA The number of amplifications 
is represented by the x-axis and ARn is represented by they-axis. ~Rn is the fluorescence 
ofthe reporter dye (FAM) divided by the fluorescence ofthe passive dye (ROX). Assays 
were performed in duplicate. 
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amplification curve and the optimal threshold. Based upon the C, value, a standard curve 
is constructed (Figure 3.17 A-B). Theoretically, the line constructed from the standard 
curve should have an R2 value of greater than 0.80 (Bio-Rad Laboratories, 2006). The 
results of the R2 and efficiency values for the transcripts are given in Table 3.8. Please 
see Appendix B for amplification plots and the standard curve specific for GAPDH. 
Table 3.8. R2 values and efficiencies for real-time PCR standard curves 
Transcript RL value Efficiency(%) 
Il-17 0.998 97.232 
RORc2 0.981 94.694 
GAPDH 0.991 93.117 
There was no amplification detected for the 5-fold dilution of HLA-04 for R0Rc2 
and IL-17. The sample was too dilute to detect RORc2 and IL-1 7, but due to the 
acceptable R2 and efficiency values, we continued with HLA-04 as the control. Next, the 
dilution of eDNA added to the reaction mixture was determined. We chose a dilution of 
eDNA that contained the least deviation between the duplicates. The eDNA dilution 
detennined was the amount added for both the positive control eDNA and the breast 
tumor sample eDNA. Table 3.9. shows the volume of stock eDNA, prepared from I )...lg of 
RNA required for each specific transcript. 
Table 3.9. Transcript specific eDNA volume for real-time PCR assays 
Transcript eDNA volume 
IL-17 1/10 J...lL 
RORc2 I J...lL 
GAPDH 1/10 ~tL 
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Figure 3.17 A. Standard curve of the threshold cycles (C J A) IL-1 7. The C values 
obtained from the amplification of log fold diluted Ill,A04. The slope of this line was-
3.39, theY-intercept was 23 .612, R2 value was 0.998 and the efficiency was 97.232%. 
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Figure 3.17B. Standard curve of the threshold cycles (CJ B) RORc2. The Ct values 
obtained from the amplification of log fold diluted HLA04. The slope of this line was -
3.45, the y-intercept was 28.282, R2 value was 0.981 and the efficiency was 94.694%. 
The Ct (y-axis) is plotted against the volume of eDNA added (x-axis). 
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3.6. Real-time PCR Analysis of IL-17 and RORc2 Transcripts in Breast Cancer Cell 
Lines 
To con finn lack of IL-17 transcripts in BCCL (Figure 3.1 0) and to detennine if 
R0Rc2 is expressed in BCCL, we perfom1ed real-time PCR assays on eDNA from BCCL 
described in Section 2.2. As shown in Figure 3. 18., we confinned that IL-1 7 transcripts 
were not detected in any of the BCCLs tested. By contrast, R0Rc2 was expressed at high 
levels in MDA-MB-435 and SK-BR-3 and at moderate levels in MDA-MB-231 and 
MDA-MB-468; very low transcripts were detected in BT-474 and none in HS-578. 
Therefore, R0Rc2 is not be a reliable lone indicator forTH 17 cells in breast tumor tissue. 
There was no eDNA available for MCF-7 and T-47D. Future experiments could analyze 
the levels of RORc2 in both of these cell lines as well as other cancer cell lines. 
3.7. Analysis of IL-17 and RORc2 transcripts in Breast Cancer eDNA by Real-Time 
PCR 
As described in Section 2.5, real-time PCR was perfonned on breast tumor eDNA 
to detennine relative levels of IL-1 7 and RORc2. The positive control eDNA was PBL 
HLA-04 and the endogenous control was GAPDH. All 65 breast tumor samples were 
initially analyzed for both IL- 17 and R0 Rc2 as eDNA was prepared at the same time as 
RIN analysis was done. The results for both sets are presented in Figures 3.1 9 and 
3.20A-B. Speannan's correlation analysis revealed no corTelation of IL- 17 real-time with 
IL-1 7 done by RT-PCR. Therefore, we repeated the real-time PCR experiments for IL-1 7 
on 49 samples with RIN values greater or equal to 5. Since the correlation between the 
two real-time PCR experiments was signifi cant (p<O.OOO), we calculated the mean for 
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Figure 3.18. BCCL expression of IL-1 7 and RORc2 as determined by real-time PCR. 6 
BCCLs (x-axis) were analyzed for transcriptional expression ofRORc2 (green bars) and 
IL-17 (blue bars). MDA-MB-435 and SK-BR-3 expressed higher quantities, whereas 
MDA 468, MDA-MB-231 , and BT-474 expressed lower levels. HS 578 did not express 
R0Rc2. No BCCL expressed IL-17. These samples were run in triplicate and the 
standard deviation is represented by the error bars. 
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Figure 3.19. Real-time IL-1 7 transcript expression in BCT samples. The figure shows 
the distribution of ll..-17 transcript levels in 49 breast tumor samples. The data are not 
normally distributed. 
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Figure 3.20A. Real-time RORc2 transcript expression in BCT samples. The figure shows 
the distribution of R0Rc2 transcript levels in 65 breast tumor samples. The data are not 
normally distributed. 
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Figure 3.20B. Real-time RORc2 transcript expression in BCT samples. The figure shows 
the distribution of R0Rc2 transcript levels in 49 breast tumor samples. The data are not 
normally distributed. 
93 
---------------------------------------- ~--
each of the 49 samples and used these values for subsequent analysis (Figure 3.19). 
To address the second aim of this project (detennine if a CO!Telation exists 
between intratumoral transcript levels of IL-17, IL-6 and RORc2), we performed a 
Speannan's co1Telation analysis among the RT-PCR data collected (IL-17 and IL-6) and 
the real-time PCR data collected (IL-17 and RORc2). As shown in Table 3. 1 0, there was 
no significant correlation of IL-17 real-time (mean) with IL-17 RT -PCR, RORc2 (real-
time) or IL-6 (RT-PCR). We had expected that the two IL-17 PCRs would correlate, 
however potential explanations for this poor correlation are discussed in Section 4.3.1. 
There was no significant correlation between the real-time RORc2 and real-time IL-1 7 (or 
RT-PCR lL-17). This is not entirely surprising because RORc2 may be present in breast 
cancer cells and IL-1 7 may be absent, as was seen in our analysis of the BCCLs (Figure 
3. 18). However, real-time levels of R0Rc2 did significantly correlate with RT-PCR 
levels of lL-6. 
Table 3.10. Spearman's correlation coefficients between IL-17 real-time, IL-1 7 RT-
PCR, R0Rc2 and IL-6 (N=49) 
IL-17 real-time IL-17 RT-PCR RORc2 IL-6 
IL-17 real time I 
lL-1 7 RT-PCR 0.605 l 
RORc2 0.703 0.644 1 
IL-6 0.334 0.763 0.286* I 
*Real-time RORc2 transcripts correlate with IL-6 RT-PCR (p=0.046) 
3. 7 .1. Derivation of a T H 17 Profile for the Breast Tumor Samples 
As T cells, other than CD4+ T H 17 cells, are reported to express RORc2, high 
RORc2 transcripts alone are not good indicators ofT H 17 cells. Additionally, 5/6 BCCLs 
expressed varying levels ofRORc2 (Section 3.6). Therefore, RORc2, on its own, is not a 
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good marker for T H 17 cells. Furthennore, IL-17 can be present in macrophages and 
therefore, IL-17 is not necessarily indicative of the presence of T H 17 cells. For these 
reason, levels of R0Rc2 and IL-17 were analyzed together to identify tumors most likely 
to have aT H 17 cell profile. Tumors with high frequencies ofT Hl7 (T H 1711i) should have 
both RORc2 and IL-l7levels higher than the median (IL-17, median = 0.0029191 (N=49) 
and RORc2, median = 0.1936 (N=49 or 65)) (see Figure 3.19 and 3.208 for data). 
Furthennore, tumors were classified as either IL-l 7hi or R0Rc2 11i if the tumor contained 
transcript levels higher than the median (ie. A tumor is classified as IL-1711i if IL-17 
transcript levels were greater than the median). If the tumor contained transcript levels 
less than or equal to the median, then the tumor was classified as IL-l i 0 /RORci 0 • Of 
the 49 tumors analyzed, 17 tumors were categorized as having a T H 1711i (IL-17 11i and 
RORc211i) profile, accomplishing our second objective. The T H 1711i profile was not found 
to correlate with intratumoral transcript levels of IL-6 (data not shown.), accomplishing 
the first aim of the third objective. 
3.7.2. Associations between T H17 and Tumor Infiltrating Immune Leukocytes 
Tumors categorized as lL-1 711i, RORc211\ and T H 1711i were analyzed for 
associations with T cells using CD3, CD4 and CDS markers and with macrophages/DCs 
using CD68 marker, previously obtained by Dr. Sharon Oldford (Section 2.1.) (Oldford et 
al., 2006). We reasoned that if our derived T H 17 profile was valid (representative of 
infiltrating CD4+ T H 17 cells), the T H 1711i category should positively associate with 
increased numbers of CD4+ T cells in tumor lesions. Oldford et al. (2006) had previously 
characterized immune cell infiltrate using CD3 (total T cells), CD4 (helper, regulatory 
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and inflammatory T cells), CD8 (cytolytic T cells) and CD68 (macrophages/dendritic 
cells), we performed a Chi square analysis using the derived IL-1 7hi/lo, RORc2hi/lo and 
T H 1 7hi/lo categories. 
Table 3.11A. Chi Square analysis for associations of IL- 17 with T cell markers in breast 
tumor samples 
Marker IL-17'11 IL-1710 P-value3 
Count (n) % Count (n) % 
CD3 
None-Small 7 29. 1 9 52.9 0.124 
Moderate-large 17 70.9 8 47.1 
CD4 
None-Small 9 39. 1 12 70.6 0.049 
Moderate-large 14 60.9 5 29.4 
CD8 
None-Small 13 76.5 12 52.2 0. 187 
Moderate-large 4 23 .5 11 47.8 
CD68 
None-Small 2 8.3 0 0 0.337 
Moderate-large 22 91.7 17 100 
a. Pearson Ch1 Square s1gmficance or F1sher' s exact test 1 f n<5 
b. Significant associations are bolded 
Table 3.118. Chi Square analysis for associations ofRORc2 with T cell markers in breast 
tumor samples 
Marker RORc2 11' RORc210 P-value3 
Count (n) % Count (n) % 
CD3 
None-Small 4 22.2 12 52.2 0.063 
M oderate-1 arge 14 77.8 1 1 47.8 
CD4 
None-Small 6 35.3 15 65.2 0.061 
Moderate-large 1 1 64.7 8 34.8 
CD8 
None-Small 8 47.1 17 73 .9 0.083 
Moderate-large 9 52.9 6 26. 1 
CD68 
None-Small 6 33.3 12 52.2 0.228 
Moderate-large 12 66.7 1 1 47.8 
a. Pearson Ch1 Square s1gmficance or Fisher's exact test if n<5 
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Table 3.11 C Chi Square analysis for associations ofT H 17 with T cell markers in breast 
tumor samples 
Marker TH17'11 TH17'0 P-valuea 
Count (n) % Count (n) % 
CD3 
None-Small 1 7.7 15 53 .6 0.006 
Moderate-large 12 92.3 13 46.4 
CD4 
None-Small 2 16.7 19 67.9 0.005 
Moderate-large 10 83.3 9 32.1 
CD8 
None-Small 4 33 .3 2 1 75 0.03 
Moderate-large 8 67.7 7 25 
CD68 
None-Small 2 15.4 16 57.1 0.012 
Moderate-large II 84.6 12 42.9 
a. Pearson Chi Square significance or Fisher's exact test if n<S 
b. Significant associations are bolded 
Table 3. 11 A shows that IL-1711 i weakly associates with increased CD4+ infiltrating 
cells. RORc2 (Table 3. 1 OB) does not associate with any of the infiltrating immune cells. 
There was a trend for high levels of both lL-1 7 and RORc2 with moderate to large 
numbers of CD4. However, Table 3. 11 C shows that the T H 1711i profile significantly 
associated with increased numbers of T cells (CD3, CD4 and CD8), but not with tumor 
infi ltrating macrophages (CD68). Therefore, these results strongly suggest that the 
derived T H 1711 i profile is a suitable marker for infiltrating CD4+ T H 17 cells. 
3.7.3. Associations between TH17 Profiles and HLA-DR Allotypes 
In the original study (Oldford et a!., 2006), HLA-DR52+ tumors were found to 
associate with decreased RFS and larger tumors. Higher IL-6 transcript levels also 
associated with decreased RFS and larger tumors. As a result, we predicted that due to 
the role of IL-6 in the differentiation ofT H 17 cells, T H 17 cells may be increased in HLA-
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DR52+ patients. Following the identification of tumors that were IL-1711 i, R0Rc211i and 
T H 1711i, we tested for associations with HLA-DR52 and the associated haplotypes (Tables 
3.12A-C) 
Table 3.12A. Chi Square analysis for associations ofTL-17 with HLA-DR allotypes 
HLA-DR allotype IL-17111 IL-1710 P-valuea 
Count (n) % Count (n) % 
DR52 
DR52-ve 13 44.8 10 50 0.72 1 
DR52+ve 16 55.2 lO 50 
DR52DQ7 
DR52DQTve 23 79.3 15 75 0.722 
DR52DQ7+ve 6 20.7 5 5 
DRB3*01 
DRB3 *0r ve 22 75.9 l3 65 0.408 
DRB3*0l+ve 7 24. 1 7 35 
DRB3 *02 
DRB3*0Tve 20 69 15 75 0.646 
DRB3*02+ve 9 31 5 25 
DRB3*03 
DRB3*03-ve 20 100 27 93.1 0.507 
DRB3*03+vc 0 0 2 6.9 
a. Pearson Chi Square Significance or Fisher's Exact Test ifn<5 
Table 3.128. Chi Square analysis for associations of RORc2 with HLA-DR al1otypes 
HLA-DR allotype RORci11 RORci0 P-valuea 
Count (n) % Count (n) % 
DR52 
DR52-ve 12 48 I 1 45.8 0.879 
DR52+ve 13 52 13 54.2 
DR57DQ7 
DR52DQTve 19 76 19 79.2 0.792 
DR52DQ7+ve 6 24 5 20.8 
DRB3*01 
DRB3*0rvc 20 80 15 62.5 0.175 
DRB3*0 f+vc 5 20 9 37.5 
DRB3*02 
DRB3*0Tve 17 68 18 75 0.588 
DRB3 *0fve 8 32 6 25 
DRB3 *03 
DRB3*0Tve 24 96 23 95 .8 1.0 
DRB3 *03+ve I 4 1 4.2 
a. Pearson Chi Square Significance or Fisher' s Exact Test if n<5 
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Table 3.12C. Chi Square analysis for associations ofT H 17 with HLA-DR allotypes 
HLA-DR allotype TH17'11 TH171o P-valuea 
Count (n) % Count (n) % 
DR52 
DR5Tve 8 47.1 15 46.9 0.990 
DR52+ve 9 52.9 17 53.1 
DR52DQ7 
DR52DQTve 14 82.4 24 75 0.725 
DR52DQ7+ve 3 17.6 8 25 
DRB3*01 
DRB3*0Fve 14 82.4 21 65.6 0.323 
DRB3*0J+vc 3 17.6 11 34.4 
DRB3*02 
DRB3*0Tve II 64.7 24 75 0.448 
DRB3*02+ve 6 35.3 8 25 
DRB3*03 
DRB3*0Tve 16 94.1 31 96.9 1.0 
DRB3*03+ve 1 5.9 1 3.1 
a. Pearson Chi Square Significance or Fisher's Exact Test ifn<5 
The data in Tables 3.12A-C, show no significant correlations between HLA-DR 
allotypes and the presence of high fL-17, RORc2 and T H 17 profiles. Analysis on 
additional tumors may answer this question more definitively. 
3. 7 .4. Associations between T H 17 Profiles and Prognostic Indicators 
A third aim of the third objective was to detennine if T H 17 associated with 
prognostic indicators. Tables 3.13A-D show there are very few associations with the 
prognostic indicators, such as tumor size, tumor type, tumor grade, clinical lymph node 
status, estrogen receptor, progesterone receptor, HER2/neu and age of diagnosis, and IL-
17, RORc2 and T H 17 profiles. 
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Table 3.13A. Chi Square analysis for associations of IL-17 with prognostic indicators 
Prognostic Factor IL-17'11 IL-1710 P-valuea 
Count (n) % Count (n) % 
Tumor Size 
:S 2 em 9 31 3 15.8 0.3 16 
> 2 em 20 69 16 84.2 
Tumor Type 
TDC 24 82.8 13 68.4 0.248 
Others 5 17.2 6 31.6 
Tumor grade 
Grade 1+11 17 60.7 17 89.5 0.046 
Grade Ill 11 39.3 2 10.5 
Clinical Node Status 
Negative 1 1 39.3 9 45 0.692 
Positive 17 60.7 11 55 
Estrogen Receptor 
ER-ve 7 24.1 6 30 0.648 
ER+ve 22 75.9 14 70 
Progesterone Receptor 
PR-ve 11 37.9 3 15 0. 112 
PR+ve 18 62.1 17 85 
HER2/Neu 
Codes 0-2 16 72.7 15 93.8 0.203 
Code 3 6 27.3 1 6.2 
a. Pearson Chi Square Significance or Fisher's Exact Test if n<5 
b. Significant associations are bolded 
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3.138. Chi Square analysis for associations of RORc2 with prognostic indicators 
Prognostic Factor RORc2 111 RORc210 P-valuea 
Count (n) % Count (n) % 
Tumor Size 
~ 2 cm 5 20 7 30.4 0.404 
> 2 em 20 80 16 69.6 
Tumor Type 
IDC 16 64 21 91.3 0.039 
Others 9 36 2 8.7 
Tumor grade 
1&2 19 79.2 16 65.2 0.285 
3 5 20.8 8 34.8 
Clinical Node Status 
Negative 12 50 8 33 .3 0.242 
Positive 12 50 16 66.7 
Estrogen Receptor 
ER·ve 6 24 7 29.2 0.682 
ER+ve 19 76 17 70.8 
Progesterone Receptor 
PR"ve 9 36 5 20.8 0.240 
PR+ve 16 64 19 79.2 
HER2/Neu 
Codes 0-2 12 75 19 86.4 0.425 
Code 3 4 25 3 13.6 
a. Pearson Chi-Square significance or Fisher ' s Exact Test if n<5 
b. Significant associations are bolded 
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3.13C. Chi Square analysis for associations ofT H 17 with prognostic indicators 
Prognostic Factor TH17 11' TH1710 P-valuea 
Count (n) % Count (n) % 
Tumor Size 
:S 2 em 3 17.6 9 29 0.497 
> 2 em 14 82.4 22 71 
Tumor Type 
IDC 12 70.6 25 80.6 0.428 
Others 5 29.4 6 19.4 
Tumor grade 
1&2 11 68.8 23 74.2 0.693 
3 5 31.2 8 25.8 
Clinical Node Status 
Negative 8 50 12 37.5 0.408 
Positive 8 50 20 62.5 
Estrogen Receptor 
ER-ve 5 29.4 8 25 0.739 
ER+ve 12 70.6 24 75 
Progesterone Receptor 
PR-ve 7 41.2 7 21.9 0.155 
PR+ve 10 58.8 25 78. 1 
HER2/Neu 
Codes 0-2 7 63.6 24 88.9 0.161 
Code 3 4 36.4 3 11 . I 
a. Pearson Chi-Square significance or Fisher's Exact Test if n<5 
3.130. Associations of IL-1 7, R0Rc2 and T H 17 with age of diagnosis 
IL-1 7 RORc2 TH17 
High Low High Low High Low 
Count 29 20 25 24 17 32 
Mean (age) 57.38 65.26 59.36 61.88 55.71 63. 19 
Significancea 0.037 0.506 0.055 
a. ANOVA 
b. Significant associations are bolded 
RORc211i associated with increased frequency of invasive ductal carcmoma. 
ANOV A analysis also revealed that T H 1711 i and IL-1 711i profiles trended with a younger 
age of diagnosis (p = 0.055 and p = 0.037, respectively). As younger age at diagnosis is a 
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poor prognosis, the presence of IL-17 or T H 17 cells may have a role in promoting breast 
cancer in younger women (Carlson et al. , 2009, McPherson et al. 2000). 
3.7.5. Analysis of HLA-DR52 stratified by IL-17 and THl7 Profiles on Age of 
Diagnosis 
Early age of onset of breast cancer was reported to be associated with an HLA-
DR52 subtype (DRB3*02) (Chaudhuri et al. , 2005) and we found that reduced age at 
diagnosis associated with both IL-l711i and T H 1711i. Therefore, we determined the 
associations of HLA-DR52, stratified by IL-1711i/Io and T H 1711i1o, with the age of diagnosis 
(Figure 3.21 A-8). As shown in Figure 3.21 B, HLA-DR52+ patients whose tumors had a 
T H 17 profile were diagnosed at a significantly younger age in comparison to those that 
are either T H 17'0 or HLA-DR5T(p=0.013). 
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Figure 3.21A. ANOVA analysis of HI.A-DR52 stratified by IL-1 7 profiles on age at 
diagnosis. The graph has the age at diagnosis on the y-axis and the IL-17 profile 
categories on the x-axis. The grey bars represent HLA-DR52- and the red bars represent 
HLA-DR52+. The mean age is given adjacent to each error bar. There were no significant 
associations. 
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Figure 3.21B. ANOVA analysis of H1A-DR52 stratified by TH1 7 profiles on age at 
diagnosis. The graph has the age at diagnosis on the y-axis and the T H 17 profile 
categories on the x-axis. The grey bars represent IaA-DR52- and the pink bars represent 
IaA-DR52+. The mean age is given adjacent to each error bar. There was a significant 
association (p=0.013). 
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3.7.6. Associations between TH17 Profiles and Overall Survival 
The final aim of the final objective was to determine whether breast cancer 
patients with a IL-l711i, RORc211i or T Hl711i profile had decreased RFS/OS than patients 
with a IL-l i 0 , RORc2'0 or T H l i o profile. To test this hypothesis, we used the Kaplan-
Meier statistical test. Patients with IL-1711 i patients did not have significantly decreased 
to time to recurrence (months until distant or regional recurrence) (Figure 3.22A) as 
compared to patients with IL-1 i 0 • However, there was a trend for IL-l711 i and decreased 
OS (months until death due to disease) (log rank = 3.161 , p = 0.075) (Figure 3.22B). 
Levels of RORc2 were found to neither correlate or trend with RFS and OS (Figure 
3.23A-B). Patients with T H 1711i profiles had a decreased RFS (log rank = 1.207 and p = 
0.272), shown in Figure 3 .24A. Furthermore, tumors with T H l711 i profiles had decreased 
OS (log rank = 2.488 and p = 0.115), shown in Figure 3.24B. However, both of these 
trends are not significant. 
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Figure 3.22A. Kaplan-Meier analysis of IL-17 prqfiles with RFS in breast cancer 
patients. A) IL-17hi (blue line) is not associated with decreased RFS in comparison to IL-
1710 (grey line). The 95% confidence intervals (CI) are listed in the top right, along with 
log rank and significance. 
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3.8. Immunohistochemistry Results 
Section 2.6. detailed the procedure for the immunohistochemistry assays. Our 
initial intent was to dual stain 40 breast tumor slides using antibodies specific for IL-17 
(cytoplasm) and RORc (nucleus). In this way, a T H 17 cell could be identified through 
protein expression if dual staining occurred. 
3.8.1. Positive and Negative Controls 
Prior to starting this study, the Drover laboratory had successfully developed an 
IHC technique for doubling staining of CD3 (cytoplasmic) and FOXP3 (nuclear) with 
antibody binding, optimized as described (Section 2.6). Figure 3.25. is a representative 
image of dual staining exhibited on a breast cancer lesion (Drover. S, unpublished data). 
Using the same antibodies, I was able to replicate these results on tonsil tissue and was 
optimistic that we would have similar success using IL 17 and RORc antibodies. While 
CD3 and FOXP3 were mouse antibodies, IL-1 7 and RORc were rabbit antibodies. To 
ensure that procedures involving rabbit antibodies performed equally well we tested a 
rabbit anti-HER2 and irrelevant rabbit IgG on control slides that were previously prepared 
in Dr. Drover 's laboratory. Sections were from FFPE cell-pellets containing HER2-
overexpressing breast cancer cells (SK-BR-3) plus B-and T-cells. The rabbit anti-HER2 
antibody bound strongly to cytoplasmic and membrane HER2, but did not bind the other 
cell types, while the irrelevant antibody did not bind appreciably (data not shown). As 
these assays were successful , we were confident that the procedures and reagents were 
performing well and proceeded with optimizing the conditions for IHC using IL-17 and 
RORc. 
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Figure 3.25. Dual IHC staining~~ sections from breast cancer lesions using antibodies 
to FOXP3 and CD3. Co-staining of the section is represented above with FOXP3 (nuclei, 
dark blue) and the cytoplasm (brown) ofCD3+T-cells. 
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3.8.2 lL-17 Immunohistochemistry Results 
With respect to the IL-1 7 antibody, we started with the recommended dilutions of 
the stock IL-17 A antibody (200 )lg/mL) which was between 1 f.l L of antibody: 50 f.lL of 
V AD ( 4 )lg/mL) and 1 11L of antibody:400 f.lL of V AD (0.5 )lg/mL) The concentration of 
0.5 )lg/mL gave the lowest background staining, with specific cytoplasmic staining. 
However, regardless of the dilution, the TL-17 antibody stained the nucleus, leading to a 
high background staining of the tonsil tissue section. 
In an attempt to decrease the nuclear staining, we decreased the concentration of 
the primary antibody, resulting in little to no specific cytoplasmic staining with weak 
nuclear staining. We also tried reducing the antigen retrieval time to 20 minutes (rather 
than 60 minutes), tried a different antigen retrieval solution (CC I) and altered the order of 
addition of the NHS and H20 2. Despite our efforts, we could not eliminate the nuclear 
staining. As the intent was to stain the nucleus as well, high nuclear background staining 
was problematic. Therefore, although there was positive cytoplasmic staining, the high 
background nuclear staining was a cause for concern as it would interfere with dual 
staining. 
3.8.3 RORc Immunohistochemistry Results 
The two RORc antibodies also produced high background staining, as well as 
cytoplasmic staining of the thymus slides. To try and eliminate the background staining, 
we tried similar procedures as we had for IL-17 A antibody optimization, but had no 
success. Furthenn ore, as mentioned in Section 2.6.5., RORc is specific for both variants 
of RORc: RORc1 and RORc2 (Medvedev eta!., 1997; Villey et a!., 1999). The primary 
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difference between the two isofonns is that RORc2 has a shorter N-terminus (Villey et 
a!., 1999). Although RORc2 is restricted to the thymus and is the transcription factor for 
T H 17 cells, RORc 1 is expressed in many tissues, including the thymus, lung, and skeletal 
muscle (Hirose eta!., 1994; Medvedev eta!., 1997; Villey eta!., 1999). Therefore, using 
an antibody specific for both isoforms is problematic as specific staining for RORc2 
cannot be determined accurately and RORc I is widely expressed. 
As a result of these problems, the IHC staining was not carried out on the breast 
tumor slides. Potential future approaches for IHC are described in Section 4.8. 
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Chapter 4. Discussion 
4.1. Summary of Research 
As described previously (Sections 1.1 and 1.6) the hypothesis and work described 
in this thesis stemmed from results of a previous study in the Drover lab (Oldford et a!. , 
2006): As IL-6 is required for the differentiation of a na·ive T cell into a T H 17 cell , we 
hypothesized that higher levels ofT H 17 cells would be present in tumors that had higher 
lL-6 transcripts and HLA-DR52+ haplotypes. 
To test these research objectives, we determined transcript levels of RORc2 and 
IL-1 7 and developed aT H 17 profile fo r each tumor. T H 1711i tumors were those with IL-1 7 
and RORc2 transcript levels greater or equal to the median (N= 17) and all other 
categories (I L-1 7<median and RORc2 >median, IL-1 7>median and RORc2<median) 
were T H 1 i 0 • We then used to these profiles in statistical tests to detennine associations 
with IL-6, infi ltrating T cells, HLA-DR52, prognostic indicators and survival. 
Although the necessary experimentation was conducted to answer our objectives, 
there are several caveats. First, the original samples size of 65 tumor samples from 65 
patients was small but was subsequently reduced to 49 tumors/patients due to the RIN 
values obtained. Secondly, RORc2 PCR analysis was done once, using real-time RT-
PCR, in triplicate and ideally should have been repeated to provide the results with 
confidence and reliability. Although the samples were run in ttiplicate, due to small 
sample quantities, these assays were only analyzed once. Thirdly, the IL-1 7 traditional 
RT-PCR and real-time PCR data does not correlate. However, we tried to overcome thi s 
obstacle by perfom1ing the real-time analysis twice and obtained an excellent correlation 
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(p<O.OOO between the two real-time PCR assays of IL-17). Lastly, we were only able to 
catTy out analysis on breast tumor mRNA, transcribed into eDNA, through PCR 
experimentation. Our initial plan was to additionally carry out IHC on paraffin embedded 
breast tumor samples. However, there was no acceptable antibody available specific for 
RORc2. Furthennore, it was challenging to optimize the IL-17 A antibody we intended to 
use. Until an antibody becomes available for RORc2, rather than RORc, we felt that we 
could not obtain an accurate representation of the T H 17 cells present in the tumor 
samples. 
The following chapter will explore our results and discuss the problems that we 
encountered. 
4.2. Breast Cancer Cell Line Preliminary Research 
Prior to analysis of the breast tumor samples, we thought it prudent to analyze 
breast cancer cell lines for IL-17, IL-6, TGF-~, RORc2 and FOXP3 transcripts. FOXP3 
is reported to be expressed in several human cancer lines, including BCCLs (Karanikas et 
al., 2008). As FOXP3 expression is used to determine a Treg phenotype, its expression in 
breast cancer cells may lead to false positives. As we were developing aT H 17 profile, it 
was important to know if BCCLs endogenously transcribe IL-1 7 or RORc2 to have a 
better understanding of the tumor milieu. Although IL-1 7 was not detected by 
conventional or real-time PCR (Figures 3.10 and 3.18), RORc2 was detected at moderate 
to high levels in 5/6 BCCLs tested by real-time PCR (Figure 3.18). Based on these 
findings, RORc2 was not considered a reliable indicator for T H 17 alone. However, 
although IL-1 7 was not detected in the BCCLs, infiltrating macrophages, which are 
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abundant in breast cancer (Oldford et a!. , 2006), produce IL-17 (Zhu et a!. , 2008). 
Therefore, IL-17 would also be considered an unreliable sole marker for T H 17 cells. 
Therefore to develop T H 17 profile, we decided to use both markers. 
IL-6 and TGF-~ are required to differentiate T H 17 cells and, therefore, the 
BCCLs mRNA was tested for presence of these cytokines transcripts. In detetmining the 
transcript levels of these cytokines in the BCCLs, one could infer if the tumor cells 
secrete these cytokines, the tumor cells could impact the plasticity ofT cells. Xu et al. 
(2007) found that CD4+CD25+FOXP3+GFP+ T regulatory cells could differentiate into 
T H 17 cells in the presence of IL-6 and absence of TGF-~ in FOXP3-GFP knock-in 
C57BL/6 mice (Xu et a!., 2007). This study supports the notion that a Treg cell can 
differentiate into a T H 17 cell , given certain conditions. Therefore, it is possible the same 
plasticity exists in a tumor environment. 
Although IL-6 and TGF-~ are required for the commitment and differentiation of 
the TH1 7 lineage, TGF-~ alone promotes a regulatory T cell response. MDA-MB-468, 
MDA-MB-435, T-470 and MCF-7 all contained higher transcript levels of TGF-~. As 
TGF-~ levels influence aT cell ' s plasticity towards a Treg phenotype (Bettelli eta!., 2006; 
Pan et a!., 20 11 ), we thought that there might be a correlation between FOXP3 and TGF -~ 
levels. However, when we analyzed the transcript levels of FOXP3 within the BCCLs, 
there were minimal amounts of FOXP3 detected in all 8 cell lines, including those with 
high TGF-~. 
Karanikas et al. (2008) analyzed FOXP3 and TGF-~ by RT-PCR and real-time 
RT-PCR, in 25 different human cancer cell lines, including MCF-7, T-470 , BT20, and 
MDA-MB-231 . They fo und high levels of FOXP3 (relative to ~-actin) in the MCF-7 cell 
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line and low amounts in T-470, MOA-M31, and BT20. With respect to TGF-~, MCF-7 
was found to express the most TGF-~ transcript. MDA-MB-231 and BT20 contained less 
TGF-~ transcript than MCF-7. They reported a significant association between levels of 
FOXP3 and TGF-~ in 25 cancer cells studied (p=0.009). Interpretation of these results 
could suggest a relationship between FOXP3 and TGF-~. When comparing findings by 
Karanikas et al. (2008) to my results, there were some discrepancies. Although, there 
was a trend for MCF-7, MOA-MB-231 and T-470 to contain higher TGF-~ transcripts, 
there were no discernible differences in the transcript levels of FOXP3 in the BCCLs that 
we analyzed. This may be attributed to a different relative control; our lab used GAPDH 
whereas their study used ~-actin. However, a more likely possibility for the differences in 
the FOXP3 data could be attributed to the culture of the breast cancer cells in different 
media. The Karanikas lab supplemented their medium with 17~-estradiol , 
hydrocortisone, sodium selenite, insulin and transferrin. These supplements may have an 
effect of transcription of FOXP3. For example, 17~-estradio l has been shown to augment 
FOXP3 expression in vitro and vivo mice studies (Polanczyk et al. , 2004), which could 
potentially example why they found increased FOXP3 in cell lines with high TGF-~ . 
4.3. PCR Analysis of Breast Tumor Samples 
Our finding that IL-17 levels obtained by conventional RT-PCR did not cotTelate 
with those obtained by conventional real-time RT-PCR was perplexing and there is no 
clear explanation. Proper optimization of RT-PCR had been done (described in Section 
3.1) and the IL-17 real-time primer kit was predesigned from Taqman Gene Expression 
assays. According to the product specifications for the IL-17 primer set (catalog number: 
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HS00174383_m1), there was only one reference sequence, NM_002190.2, which 
corresponds to IL-17 A. The amplicon length of the product was 80 base pairs, which is 
typical for real-time RT-PCR products (less than I 00 base pairs). The product size was 
confirmed using an agarose gel (data not shown). Therefore, as this product was ready 
made and used in previous publications for identifying the IL-17 transcript, the real-time 
RT-PCR primers should be more accurate and reliable than conventional RT-PCR. 
As well, there are significant limitations to traditional PCR. In particular, the 
results are obtained from the end point of the reaction. End point detection has poor 
precision, low sensitivity, low resolution, results are not expressed numericall y and 
ethidum bromide staining is not very quantitative. Bands are quantified through 
digitization, which varies according to programs and is dependent upon the image quality 
produced by the equipment. Real-time PCR is able to detect PCR products as the reaction 
is proceeding. Therefore, the results are obtained linearly as opposed to the end-point. 
Taking these factors into consideration we choose to proceed to use the real-time values 
of IL-17 for the development of aT H 17 profile. 
Real-time levels of R0Rc2 were detennined for the 65 samples, although, the 49 
samples with RIN 2:5 were used for the T H 17 profile. There was no significant 
correlation noted between the RORc2 and IL-1 7 transcripts, regardless of whether the IL-
17 transcript levels were detennined by real-time PCR or RT-PCR. This was somewhat 
surprising as we expected a positive correlation between the main cytokine (IL-1 7 A) and 
the transcription factor (RORc2) for T H 17 cells. However, the fact that the RORc2 did 
not correlate with IL-1 7 transcript levels is not unique to the T H 17 cell profile as similar 
findings were described by Kitamura et a/. (2005) concerning TH2 cells. This study 
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reported that the transcription factor, GATA3, did not cotTespond to mRNA levels of 
T H2 cytokines IL-4 and IL-5 (Kitamura et al., 2005). 
Additional studies could analyze the transcript or protein levels of ST AT3 as 
STA T3 is a precursor to RORc2. IL-23R levels could also be analyzed as it is required 
for the stabilization ofT H 17 cells. Having a better understanding of these levels with 
respect to both IL-17 and RORc2 could assist in detennining whether the real-time or the 
RT-PCR method is more reliable. 
4.4. The Relationships between IL-6 and the TH17 Profile within the Breast Tumor 
Samples 
Although TL-6 transcripts had been previously done once on breast cancer samples 
(Oldford et al. , 2006), we chose to repeat it on the samples. The previous assay used P-
actin as the endogenous control. As we were using GAPDH as the endogenous control 
for IL-1 7 and RORc2 assays, we re-analyzed IL-6 samples to determine the relative 
quantity present with respect to GAPDH. Furthermore, the gels were analyzed using 
different imaging and digitalization software. Despite these differences, using 
Spearman 's correlation test, IL-6 transcript levels significantly correlated with values 
previously collected (p=0.05). This significant correlation provides us with confidence 
that the transcript levels of IL-6 reported in this thesis are val id. 
One of the aims for this thesis was to detennine if a relationship existed between 
IL-6 and T H 17 markers and T H 17 cells. Although IL-6 did not correlate with IL- 17 or the 
T H 1711 i profile, we found an association between RORc2 and IL-6 (p=0.046). As 
described in Section 1.3.4., IL-6 is required to activate STAT3, which subsequently leads 
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to RORc2 express1on (Xu et al. , 2007) and therefore, we would expect a correlation 
between RORc2 and IL-6. Yet, because there was a lack of correlation between IL-6 and 
IL-17 and T Hl711i, we suggest that T H 17 cells may be recruited to the tumor site, rather 
than differentiate within the site. This could be explored by determining if the ligands, 
CXCL12 and/or CCL20, which bind to the chemokine receptors, CXCR4 and CCR6 that 
are abundantly expressed on T H 17 cells (Zou et al. ,201 0; Yamazaki et al. , 2008; Boisvert 
et al., 201 0), are secreted by the tumor cells. Their presence would suggest that T H 17 
cells migrate to, rather than differentiate in the tumor milieu. Detennining if these ligands 
are present in the tumor milieu may provide us insight into whether T H 17 cells migrate to 
or differentiate in a tumor. 
4.5. TH17 Profile and Associations with HLA-DR Allotypes 
Studies have found that certain HLA alleles associate with the development of 
cancer, Chadhuri et a!. (2000) reported that a subtype of HLA-DR52 (DRB3*02) was 
increased in younger patients with breast cancer in comparison to age-matched healthy 
controls. Further, the Drover lab found that HLA-DR52 was associated with larger 
tumors and decreased recurrence free survival in breast cancer patients. Such studies 
support the concept that certain MHC class II alleles associate with cancer prevalence or 
poor prognoses in cancer because tumor associated antigens presented in the context of 
particular MHC class II alleles may promote suppression of the immune system, 
conferring an advantage to the cancer. We found no association between the relevant 
HLA-DR subtypes and IL-17, RORc2 and TH17 (Tables 3.11 A-C). Therefore, within the 
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limitations of this small samples size, it seems that HLA-DR52 alleles may not promote 
T H 17 development in breast tumor patients. 
4.6. T Hl7 Profile Associations with Prognostic Indicators 
As described in the introduction, breast cancer is a complex disease with many 
different molecular subtypes, which vary in their prognosis and treatment. We wanted to 
determine ifT H 17 markers and T H 17 cells associated with prognostic indicators, honnone 
receptors and breast cancer type. If T H 17 cells were found to associate with a poor or a 
good prognostic indicator, then future experiments to determine if T H17 cells were 
mechanistically associated with the outcome could be conducted. 
Tumor size, tumor type, tumor grade, clinical lymph node status, ER presence, PR 
presence, HER2/neu presence and age of diagnosis were all analyzed for associations 
with IL-17, RORc2 and TH17 profiles. 
IL-17'0 was found to associate with low tumor grades (p=0.030). As a result, 
blocking IL-1 7 and reducing intratumoral levels could hinder tumor development. This 
may be a reflection on the ability of IL-1 7 to promote angiogenesis through inducing 
VEGF and CXCL-8 production (Figure 1.6). Interestingly, a study by Fialova et al. 
(20 12) found higher IL-1 7 A levels with limited stage ovarian cancer (Fialova et a!., 
2012), however, it is difficult to directly compare breast cancer and ovarian cancer. 
Although others (Horlock et a!., 2009) have suggested an association between 
HER2+ breast cancer and increased levels ofT H 17, we found no such association. This 
could be due to the methodology as we analyzed T H 17 transcripts from breast cancer 
tissue. Horlock et a!. (2009) enumerated CD4+IL-17+ cells in the peripheral blood of 
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breast cancer patients and on comparing the numbers ofT H 17 cells to healthy controls, 
they found T H 17 cells to be increased in HER2+ patients. 
Our finding that IL-17 11i correlated to younger ages for diagnosis, a poor 
prognostic indicator, suggests IL-17 may have a role in promotion of breast cancer in 
younger women (Carlson et a!. , 2009, McPherson et al ,. 2000). However, a mechanistic 
approach to IL-17 and promotion of breast cancer in younger women has yet to be found. 
T H l7 11i, like IL-17 11i, correlated with a younger age at diagnosis. Due to Chaudhuri 's 
findings (2000), which related HLA-DR52 and a younger age of diagnosis, we decided to 
split our samples into IL-17 11i/Io and T H 17hi/Io categories and analyze the data for 
associations with HLA-DR52 and younger age at diagnosis (Figure 3.2 1A-B). 
T Hl711i/HLA-DR52+ tumors had the youngest age at diagnosis (mean age at diagnosis 
(OX) = 49) and this correlation was significant (p=O.Ol3). IL-1 7hi/HLA-DR52+ patients 
had a lower mean age of diagnosis (mean = 55), but this was not a significant 
relationship. As HLA-DR52 heterodimers would present breast tumor antigens to T cells, 
it is possible that in younger individuals, with higher hormone levels, that CD4+ T cells 
are polmized towards the T H 17 profile. Future studies could analyze the effect estrogen 
has on T H 17 cells in vitro or in vivo. 
With respect to RORc2, there was a significant association between RORc2'0 and 
invasive ductal tumors (p=0.026). . Since the breast cancer cell lines had increased 
R0Rc2, it could potentially be a marker for ductal cancer and be able to differentiate it 
from lobular cancer. 
We theorized that T H l7hi/IL-17 11i could associate with positive clinical lymph node 
status because IL-17 could led to the secretion of VEGF, which could allow the 
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movement of breast cancer cells into lymph nodes (Murugaiyan et a!., 2009). However, 
this was not the case as we found no association between positive lymph node status and 
T H 1711i/ IL-l711i. Furthermore, Yang et al. (20 12) found that there was a negative 
association between T H 17 levels and increased numbers of metastatic nodes in breast 
cancer patients. Future experiments could explore the possibility that T H 17 cells are 
having an anti-tumor effect (Figure 1.5) by attracting innate cells into the tumor 
microenvironment. Detennining the levels of CXCL9, CXCLI 0, NK cells and dendritic 
cells within the tumor environment with respect to T H 17 cells could be an aim of future 
experiments. Such experiments could clarify the role of T H 17 cells in tumor 
microenvironments. 
4.7. T H17 Profile Associations with Survival 
The last objective was to determine if survival or recurrence was related to IL- 17, 
RORc2 or T H 17 profiles. Stemming back to the research by Old ford, it was noted that IL-
611i associated with decreased survival. Therefore, we thought that T H 1711i would also 
correlate to decreased survival. 
With respect to the T H 17 cell markers, IL-1 711i and T H 1711i trended with decreased 
OS but these were not significant associations. However, expanding the sample size 
would test more rigorously whether T H 17 cells in promote decreased survival breast 
cancer. Furthennore, expansion of the sample size would allow additional statistical 
analysis, such as a multivariate Cox analysis, to test for associations with survival. In 
contrast to our trend, Kryczek et al. (2009) found a relationship between improved patient 
outcome and T H 17 cells in ovarian cancer. However, it is difficult to compare ovarian 
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and breast cancer. Expanding the sample size may provide greater insight into the role of 
T H 17 cells and RFS and OS. 
4.8. Concluding Remarks and Future Studies 
We had hypothesized that higher levels ofT H 17 cells would be present in tumors 
that had high lL-6 transcripts and HLA-DR52+ haplotypes. However, we found that 
neither 1L-611 i nor HLA-DR52 associated with increased TH17 cells. We also determined 
that there were few significant associations between T H 17 markers/profile and prognostic 
indicators. However, we did note that both 1L-1711i and T H 1711i associated with younger 
age of breast cancer at diagnosis. Fmiher, due to the Chaudhuri et al. (2000) study, 
which reported that HLA-DR52 also correlated to a younger age at diagnosis, we 
detennined that tumors with HLA-DR52+/T H 1711i profiles had a significantly lower age at 
diagnosis than the tumors that were either HLA-DR52- or T H 1710• 
determined that T H 1711 i did trend with decreased overall survival. 
Lastly, we 
Further studies and alternative experiments could be carried out to support our 
findings. With respect to the PC R samples, future experiments could be conducted 
through real-time RT-PC R only. We had a number of problems regarding conventional 
RT-PC R and as real-time RT-PCR is more sensi tive and accurate, one could use real-time 
PCR alone. Additionally, analyzing mRNA levels of additional T H 17 markers in 
combination with IL-17 and RORc2, such as STAT3 or IL-2 1, would give more insight 
into the presence ofT H 17 cells in the breast tumor samples. 
This study focused on mRNA transcripts levels. Although our initial intent was to 
analyze protein expression through dual staining IHC, problems were encountered 
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concemmg availability of a specific RORc2 antibody and optimization of IL-17 
antibodies. Future studies may be able to use ST A T3 as a nuclear marker, rather than 
RORc2, and try different optimization techniques for IL-17. Further, to gain an accurate 
representation of the frequency of T H 17 cells in breast tumors, having healthy breast 
tissue for a comparison would be ideal. 
A major caveat of this project was the small number of samples. Expanding the 
sample size could clarify trends which were observed in this study, provide confidence 
for significant associations that were calculated and permit the use of additional statistical 
tests (multivariate Cox analysis). Furthennore, having healthy breast tumor tissue for 
mRNA and protein analysis would be a useful control. We used stimulated PBLs as the 
positive control for IL-17 and RORc2 and the expression of both targets were quite high 
relative to the levels observed in the breast tumor samples. Having samples of healthy 
breast tissues would allow for a more accurate and in depth analysis of the potential 
increase or decrease of T H 17 markers/cells that occurs with breast cancer patients. 
Additionally, analyzing the peripheral blood of breast cancer patients would provide more 
infonnation on the circulating T cells, the prevalence ofT H 17 cells in the PBL population 
and associations between PBL T H 17 populations and prognostic indicators. 
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Appendix A 
Stage TNM 
0 TO NO MO 
I Tl NO MO 
II TONI MO, Tl Nl MO, T2 NO MO, T2 Nl MO, T3 NO MO 
HI TO N2 MO, Tl N2 MO, T2 N2 MO, T3 Nl-2 MO, T4 N l-3 MO 
IV AnyT AnyN Ml 
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Appendix B 
i) 
G.A.PDH 
10 
0 .1 
0 .01 
0.001 
0.0001 
0 .00001 
0 .000001 
Cycle 
Appendix B. i. Determining the optimal dilution of eDNA for real-time assays (GAPDH) 
amiplification. Log fold dilutions of HLA04 were amplified in the StepOne Real-Time 
PCR machine over 40 cycles. The red line represents amplification of 1 ~of eDNA, the 
yellow lines represents amplification of a 1 fold log dilution of cDN A, the light green line 
represents amplification of a 2 fold log dilution of cDN A and the dark green lines 
represents amplification of a 3 fold log diltuion of eDNA~ of eDNA and the blue line 
represents amplification of a 5 fold log dilution of eDNA The number of amplifications 
is represented by the x-axis and ~is represented by they-axis. ~Rn is the fluorescence 
ofthe reporter dye (FAM) divided by the fluorescence ofthe passive dye (ROX). Assays 
were performed in duplicate. 
143 
ii) 
Standard Curve 
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Appendix B. ii. Standard curve of the threshold cycles (CJ (GAPDH). The Ct values 
obtained from the amplification of log fold diluted HLA04. The slope of this line was -
3.499, they-intercept was 20.423, R2 value was 0.991 and the efficiency was 93.117%. 
The Ct (y-axis) is plotted against the volume of eDNA added (x-axis). 
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